44_CD
44_CD
Cambridg_NN
Cambridge_NN
e_SYM
Antibody_NN
Antibody_NN
T_NN
Technolo_NN
echnolog_NN
gy_NN
y_VB
Gr_NN
Group_NN
plc_NN
oup_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
1_CD
Accounting_GER
policies_NN
A_DT
summary_NN
of_PIN
the_DT
principal_JJ
accounting_GER
policies_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
These_DEMP
have_VPRT
all_QUAN
been_VBN [PASS]
applied_VBN
consistently_RB
throughout_PIN
the_DT
periods_NN
covered_VBN [WZPAST]
by_PIN
this_DEMO
report_NN
._.
Basis_NN
of_PIN
accounting_GER
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
and_CC
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
standards_NN
in_PIN
the_DT
United_NN
Kingdom_NN
UK_NN
GAAP_NN
._.
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
Group_NN
financial_JJ
statements_NOMZ
consolidate_VPRT
the_DT
financial_JJ
statements_NOMZ
of_PIN
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_VPRT
the_DT
Company_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
collectively_RB
the_DT
Group_NN
,_,
drawn_VBN
up_RP
to_PIN
30_CD
September_NN
each_QUAN
year_NN
._.
All_QUAN
intercompany_NN
balances_NN
and_PHC
transactions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
on_PIN
consolidation_NOMZ
._.
The_DT
acquisition_NOMZ
of_PIN
Cambridge_NN
Antibody_NN
Technology_NN
Limited_NN
CAT_NN
Limited_NN
,_,
by_PIN
way_NN
of_PIN
share_NN
for_PIN
share_NN
exchange_NN
on_PIN
20_CD
December_NN
1996_CD
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
group_NN
reconstruction_NOMZ
in_PIN
accordance_NN
with_PIN
Financial_NN
Reporting_GER
Standard_NN
FRS_NN
6_CD
._.
Consequently_CONJ
,_,
consolidated_JJ
financial_JJ
information_NOMZ
is_VPRT [PASS]
presented_VBN
as_IN
if_COND
the_DT
Company_NN
has_VPRT [SPAU] [PEAS]
always_RB
owned_VBN
CAT_NN
Limited_NN
._.
Otherwise_CONJ
,_,
the_DT
results_NN
of_PIN
subsidiaries_NN
acquired_VBN [WZPAST]
are_VPRT [PASS]
consolidated_VBN
for_PIN
the_DT
periods_NN
from_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
control_NN
passed_VBD
._.
Such_JJ
acquisitions_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
acquisition_NOMZ
method_NN
._.
The_DT
results_NN
of_PIN
subsidiaries_NN
disposed_VBN [WZPAST]
of_PIN
are_VPRT [PASS]
consolidated_VBN
up_RP
to_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
control_NN
passed_VBD
._.
The_DT
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
dealt_VBD
with_PIN
in_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
3,090,000_CD
2001_CD
:_:
7,838,000_CD
._.
As_IN
provided_VBN
by_PIN
S._NN
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
company_NN
only_DWNT
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
in_PIN
respect_NN
of_PIN
the_DT
Company_NN
._.
Goodwill_NN
Goodwill_NN
,_,
representing_VBG [PRESP]
the_DT
excess_NN
of_PIN
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
,_,
is_VPRT [PASS]
capitalized_VBN
as_IN
an_DT
asset_NN
on_PIN
the_DT
balance_NN
sheet_NN
._.
On_PIN
disposal_NN
of_PIN
a_DT
previously_TIME
acquired_VBN
business_NOMZ
,_,
the_DT
attributable_JJ
amount_NN
of_PIN
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
under_IN
the_DT
then_RB
applicable_JJ
accounting_GER
policy_NN
is_VPRT [PASS]
included_VBN
in_PIN
determining_VBG [SUAV] [PRIV]
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
Turnover_NN
Turnover_NN
principally_RB
consists_VPRT
of_PIN
income_NN
received_VBN [WZPAST]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
from_PIN
license_NN
fees_NN
,_,
technical_JJ
milestones_NN
,_,
clinical_JJ
milestones_NN
,_,
fees_NN
for_PIN
research_NN
and_PHC
development_NOMZ
services_NN
,_,
payments_NOMZ
for_PIN
purchased_VBN
rights_NN
,_,
and_ANDC
royalties_NN
._.
These_DEMP
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
trade_NN
discounts_NN
,_,
VAT_NN
and_CC
other_JJ
sales_NN
related_VBN
taxes_NN
._.
A_DT
description_NOMZ
of_PIN
the_DT
various_JJ
elements_NOMZ
of_PIN
turnover_NN
and_CC
their_TPP3
accounting_GER
policies_NN
is_VPRT [PASS]
given_VBN
below_PLACE
._.
Licence_NN
fees_NN
Licence_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
licence_NN
term_NN
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
where_RB
relevant_JJ
._.
In_PIN
circumstances_NN
where_RB
no_SYNE
such_JJ
defined_VBN
period_NN
exists_VPRT
,_,
the_DT
licence_NN
fee_NN
is_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patents_NN
licenced_VBD
._.
For_PIN
licence_NN
fees_NN
where_RB
a_DT
proportion_NOMZ
of_PIN
the_DT
fee_NN
is_VPRT [BEMA]
creditable_PRED
against_PIN
research_NN
and_PHC
development_NOMZ
services_NN
to_TO
be_VB [PASS]
provided_VBN
in_PIN
the_DT
future_NN
that_DEMO
proportion_NOMZ
of_PIN
the_DT
amount_NN
received_VBN [WZPAST]
is_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
the_DT
services_NN
are_VPRT [PASS]
rendered_VBN
._.
Technical_NN
milestones_NN
During_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
programs_NN
the_DT
Group_NN
receives_VPRT
non-refundable_JJ
milestone_NN
payments_NOMZ
when_RB
it_PIT
achieves_VPRT
certain_JJ
defined_VBN
technical_JJ
criteria_NN
._.
Such_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
based_VBN
on_PIN
the_DT
percentage_NN
of_PIN
completion_NOMZ
of_PIN
the_DT
relevant_JJ
research_NN
and_PHC
development_NOMZ
program_NN
subject_NN
to_PIN
the_DT
total_JJ
revenue_NN
recognized_VBN [PRIV] [WZPAST]
being_VBG [PASS]
limited_VBN
to_PIN
the_DT
aggregate_JJ
amount_NN
of_PIN
non-refundable_JJ
milestone_NN
payments_NOMZ
received_VBD
._.
The_DT
percentage_NN
completion_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
effort_NN
in_PIN
hours_NN
incurred_VBN
compared_VBN
to_PIN
total_JJ
estimated_JJ
effort_NN
for_PIN
the_DT
program_NN
._.
Clinical_JJ
milestones_NN
The_DT
Group_NN
receives_VPRT
non-refundable_JJ
clinical_JJ
development_NOMZ
milestones_NN
when_RB
a_DT
licensee_NN
or_CC
corporate_JJ
partner_NN
achieves_VPRT
key_JJ
stages_NN
in_PIN
clinical_JJ
trials_NN
which_WDT [WHOBJ]
they_TPP3
are_VPRT
conducting_VBG
with_PIN
a_DT
view_NN
to_PIN
the_DT
ultimate_JJ
commercialisation_NOMZ
of_PIN
a_DT
product_NN
derived_VBN
using_VBG
the_DT
Groups_NN
proprietary_JJ
technology_NN
._.
Such_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
received_VBN
except_PIN
that_DEMO
if_COND
such_JJ
milestones_NN
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
a_DT
relevant_JJ
amount_NN
will_PRMD
be_VB [PASS]
deferred_VBN
and_PHC
released_VBN
as_IN
the_DT
related_JJ
royalty_NN
payments_NOMZ
are_VPRT [PASS]
received_VBN
._.
Research_NN
and_PHC
development_NOMZ
services_NN
The_DT
Group_NN
provides_VPRT
research_NN
and_PHC
development_NOMZ
services_NN
to_PIN
certain_JJ
corporate_JJ
collaborators_NN
,_,
usually_RB
in_PIN
the_DT
form_NN
of_PIN
a_DT
defined_VBN
number_NN
of_PIN
the_DT
Groups_NN
employees_NN
working_VBG [WZPRES]
under_IN
the_DT
direction_NOMZ
of_PIN
the_DT
collaborator_NN
to_TO
further_VB
the_DT
collaborators_NN
research_NN
and_PHC
development_NOMZ
effort_NN
._.
Such_JJ
contracts_NN
are_VPRT [PASS]
made_VBN
on_PIN
the_DT
basis_NN
of_PIN
Full_NN
Time_NN
Equivalent_NN
FTE_NN
employees_NN
and_CC
are_VPRT [PASS]
charged_VBN
at_PIN
a_DT
specified_VBN
rate_NN
per_PIN
FTE_NN
._.
Revenues_NN
from_PIN
FTE_NN
services_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
services_NN
are_VPRT [PASS]
rendered_VBN
._.
Purchased_VBN
rights_NN
Under_IN
an_DT
agreement_NOMZ
with_PIN
Drug_NN
Royalty_NN
Corporation_NOMZ
DRC_NN
the_DT
Group_NN
received_VBD
a_DT
payment_NOMZ
of_PIN
1.5_CD
million_CD
in_PIN
1994_CD
in_PIN
return_NN
for_PIN
rights_NN
to_PIN
a_DT
percentage_NN
of_PIN
revenues_NN
and_CC
certain_JJ
other_JJ
payments_NOMZ
received_VBN [WZPAST]
by_PIN
the_DT
Group_NN
over_IN
a_DT
period_NN
terminating_VBG [WZPRES]
in_PIN
2009_CD
._.
The_DT
Groups_NN
accounting_VBG [WZPRES]
policy_NN
is_VPRT
that_DEMO
the_DT
payment_NOMZ
be_VB [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
ratably_RB
over_IN
the_DT
period_NN
for_PIN
which_WDT [PIRE]
rights_NN
were_VBD [PASS]
purchased_VBN
._.
On_PIN
2_CD
May_POMD
2002_CD
the_DT
Group_NN
bought_VBD
out_PIN
this_DEMO
royalty_NN
obligation_NOMZ
with_PIN
the_DT
issue_NN
of_PIN
CAT_NN
shares_NN
to_PIN
DRC_NN
._.
The_DT
remaining_VBG
balance_NN
of_PIN
deferred_JJ
income_NN
has_VPRT [PEAS]
been_VBN [PASS]
released_VBN
in_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2002_CD
._.
Royalties_NN
Royalty_NN
income_NN
is_VPRT [BYPA]
generated_VBN
by_PIN
sales_NN
of_PIN
products_NN
incorporating_VBG [WZPRES]
the_DT
Groups_NN
proprietary_JJ
technology_NN
and_CC
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
received_VBN
._.
The_DT
Group_NN
has_VPRT
yet_RB
to_TO
receive_VB
any_QUAN
significant_JJ
royalty_NN
payments_NOMZ
._.
45_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Government_NOMZ
grants_NN
Grants_NN
of_PIN
a_DT
revenue_NN
nature_NN
are_VPRT [PASS]
credited_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
the_DT
related_JJ
expenditure_NN
is_VPRT [PASS]
incurred_VBN
._.
Taxation_NOMZ
Current_NN
tax_NN
,_,
including_VBG
UK_NN
corporation_NOMZ
tax_NN
and_CC
foreign_JJ
tax_NN
,_,
is_VPRT [PASS]
provided_VBN
at_PIN
amounts_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
or_CC
recovered_VBN
using_VBG
the_DT
tax_NN
rates_NN
and_PHC
laws_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [BYPA]
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
adopted_VBN
FRS_NN
19_CD
Deferred_NN
Tax_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
on_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
result_VPRT
in_PIN
an_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
to_TO
pay_VB
more_EMPH
tax_NN
,_,
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
,_,
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
a_DT
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
Timing_NN
differences_NN
arise_VPRT
from_PIN
the_DT
inclusion_NN
of_PIN
items_NN
of_PIN
income_NN
and_PHC
expenditure_NN
in_PIN
taxation_NOMZ
computations_NOMZ
in_PIN
periods_NN
different_JJ
from_PIN
those_DEMO
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
financial_JJ
statements_NOMZ
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
not_XX0
provided_VBN
on_PIN
timing_NN
differences_NN
arising_VBG [WZPRES]
from_PIN
the_DT
revaluation_NOMZ
of_PIN
fixed_JJ
assets_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
sell_VB
the_DT
asset_NN
,_,
or_CC
on_PIN
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
and_PHC
associates_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
to_TO
remit_VB
these_DEMO
earnings_GER
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
Research_NN
and_PHC
development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
as_IN
incurred_VBN
._.
Collaboration_NOMZ
arrangements_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
certain_JJ
collaboration_NOMZ
arrangements_NOMZ
whereby_OSUB
the_DT
parties_NN
agree_VPRT [SUAV] [PUBV]
to_TO
work_VB
jointly_RB
on_PIN
research_NN
and_PHC
development_NOMZ
of_PIN
potential_JJ
therapeutic_JJ
products_NN
._.
Under_IN
such_JJ
arrangements_NOMZ
the_DT
parties_NN
agree_VPRT [SUAV] [PUBV]
which_WDT [WHCL]
elements_NOMZ
of_PIN
research_NN
and_PHC
development_NOMZ
each_QUAN
will_PRMD
perform_VB
._.
These_DEMO
arrangements_NOMZ
do_VPRT
not_XX0
include_VB
the_DT
creation_NOMZ
of_PIN
any_QUAN
separate_JJ
entity_NOMZ
to_TO
conduct_VB
the_DT
activities_NOMZ
nor_SYNE
any_QUAN
separate_JJ
and_PHC
distinct_JJ
assets_NN
or_CC
liabilities_NOMZ
._.
The_DT
parties_NN
agree_VPRT [SUAV] [PUBV]
that_THVC
the_DT
combined_VBN
cost_NN
of_PIN
all_QUAN
relevant_JJ
activities_NOMZ
will_PRMD
be_VB [BYPA]
borne_VBN
by_PIN
the_DT
parties_NN
in_PIN
a_DT
particular_JJ
proportion_NOMZ
and_CC
that_DEMO
net_JJ
revenues_NN
derived_VBN [WZPAST]
from_PIN
sales_NN
of_PIN
any_QUAN
resulting_VBG
product_NN
will_PRMD
be_VB [PASS]
shared_VBN
similarly_CONJ
._.
The_DT
sharing_GER
of_PIN
costs_NN
will_PRMD
result_VB
in_PIN
balancing_VBG
payments_NOMZ
between_PIN
the_DT
parties_NN
and_CC
such_JJ
payments_NOMZ
receivable_JJ
or_CC
payable_JJ
will_PRMD
be_VB [SPAU] [PASS]
respectively_RB
added_VBN [PUBV]
to_TO
or_CC
deducted_VBN
from_PIN
research_NN
and_PHC
development_NOMZ
costs_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Any_QUAN
amounts_NN
receivable_JJ
or_CC
payable_JJ
at_PIN
a_DT
period_NN
end_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
under_IN
debtors_NN
or_CC
creditors_NN
._.
Pension_NN
costs_NN
The_DT
Group_NN
operates_VPRT
a_DT
group_NN
personal_JJ
pension_NN
plan_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
a_DT
defined_VBN
contribution_NOMZ
scheme_NN
._.
The_DT
amount_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
respect_NN
of_PIN
pension_NN
costs_NN
is_VPRT [BEMA]
the_DT
Groups_NN
contributions_NOMZ
payable_JJ
in_PIN
the_DT
year_NN
._.
Differences_NN
between_PIN
contributions_NOMZ
payable_JJ
in_PIN
the_DT
year_NN
and_PHC
contributions_NOMZ
actually_RB
paid_VBN
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
either_DT
accruals_NN
or_CC
prepayments_NOMZ
in_PIN
the_DT
balance_NN
sheet_NN
._.
Intangible_JJ
assets_NN
Purchased_VBN
intangible_JJ
assets_NN
excluding_VBG [WZPRES]
goodwill_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
assets_NN
on_PIN
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
on_PIN
acquisition_NOMZ
and_CC
amortised_VBN
over_IN
their_TPP3
useful_JJ
economic_JJ
lives_NN
,_,
subject_JJ
to_PIN
reviews_NN
for_PIN
impairment_NOMZ
when_RB
events_NN
or_CC
change_NN
of_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
using_VBG
cash_NN
flow_NN
projections_NOMZ
._.
To_PIN
the_DT
extent_NN
carrying_VBG [WZPRES]
values_NN
exceed_VPRT
fair_JJ
values_NN
,_,
an_DT
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
and_PHC
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
that_DEMO
period_NN
._.
This_DEMP
applies_VPRT
to_PIN
intangibles_NN
purchased_VBN [WZPAST]
separately_RB
from_PIN
a_DT
business_NOMZ
and_CC
also_RB
to_PIN
intangibles_NN
acquired_VBN
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
if_COND
their_TPP3
value_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
on_PIN
initial_JJ
recognition_NOMZ
._.
The_DT
Groups_NN
purchased_VBD
intangible_JJ
assets_NN
include_VPRT
access_NN
to_PIN
intellectual_JJ
property_NN
and_PHC
options_NOMZ
for_PIN
product_NN
development_NOMZ
rights_NN
which_WDT [WHSUB]
are_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
seven_CD
years_NN
and_CC
also_RB
include_VPRT
certain_JJ
patents_NN
which_WDT [WHSUB]
are_VPRT
being_VBG [PASS]
written_VBN [PUBV]
off_PIN
over_IN
their_TPP3
term_NN
to_TO
expiry_VB
which_WDT
is_VPRT [BEMA]
between_PIN
12_CD
and_CC
16_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
When_RB
reviewing_VBG
all_QUAN
these_DEMO
assets_NN
for_PIN
impairment_NOMZ
the_DT
Directors_NN
have_VPRT [PEAS]
considered_VBN [PRIV] [THATD]
future_JJ
cash_NN
flows_VPRT
arising_VBG
._.
Tangible_JJ
fixed_JJ
assets_NN
Tangible_JJ
fixed_VBN
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
,_,
net_NN
of_PIN
depreciation_NOMZ
and_CC
any_QUAN
provision_NN
for_PIN
impairment_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
all_QUAN
tangible_JJ
fixed_JJ
assets_NN
other_JJ
than_PIN
freehold_JJ
land_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
,_,
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
,_,
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Freehold_NN
buildings_GER
:_:
over_IN
12_CD
years_NN
._.
Office_NN
and_PHC
laboratory_NN
equipment_NOMZ
:_:
25_CD
%_NN
per_PIN
annum_NN
._.
Fixtures_NN
and_PHC
fittings_GER
:_:
over_IN
either_DT
5_CD
or_CC
20_CD
years_NN
or_CC
the_DT
remaining_VBG
lease_NN
term_NN
if_COND
less_JJ
._.
Investments_NOMZ
Fixed_NN
asset_NN
investments_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
._.
Liquid_NN
resources_NN
Liquid_NN
resources_NN
comprise_VPRT
negotiable_JJ
securities_NOMZ
and_PHC
term_NN
deposits_NN
and_CC
are_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
with_PIN
accrued_VBN
interest_NN
included_VBN [WZPAST]
in_PIN
debtors_NN
._.
Where_RB
relevant_JJ
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
such_OSUB
that_NULL
cost_NN
plus_PIN
accrued_VBN
interest_NN
does_VPRT
not_XX0
exceed_VB
market_NN
value_NN
._.
46_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
1_CD
Accounting_GER
policies_NN
continued_VBD
Foreign_JJ
currency_NN
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
are_VPRT [PASS]
reported_VBN [PUBV]
at_PIN
the_DT
rates_NN
of_PIN
exchange_NN
prevailing_VBG [WZPRES]
at_PIN
that_DEMO
date_NN
._.
Any_QUAN
gain_NN
or_CC
loss_NN
arising_VBG [WZPRES]
from_PIN
a_DT
change_NN
in_PIN
exchange_NN
rates_NN
subsequent_JJ
to_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
is_VPRT [PASS]
included_VBN
as_IN
an_DT
exchange_NN
gain_NN
or_CC
loss_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
and_CC
their_TPP3
balance_NN
sheets_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
translation_NOMZ
of_PIN
the_DT
opening_GER
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
are_VPRT [PASS]
dealt_VBN
with_PIN
through_PIN
reserves_NN
._.
Leases_NN
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
,_,
which_WDT [SERE]
confer_VPRT
rights_NN
and_PHC
obligations_NOMZ
similar_JJ
to_PIN
those_DEMP
attached_VBN
to_TO
owned_VBN
assets_NN
,_,
are_VPRT [PASS]
capitalized_VBN
as_IN
tangible_JJ
fixed_JJ
assets_NN
and_CC
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
terms_NN
and_CC
their_TPP3
useful_JJ
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
obligations_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
elements_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
of_PIN
the_DT
leases_NN
to_TO
produce_VB
a_DT
constant_JJ
rate_NN
of_PIN
charge_NN
on_PIN
the_DT
balance_NN
of_PIN
capital_NN
repayments_NOMZ
outstanding_JJ
._.
Hire_VB
purchase_NN
transactions_NOMZ
are_VPRT [PASS]
dealt_VBN
with_PIN
similarly_CONJ
,_,
except_PIN
that_DEMO
assets_NN
are_VPRT [PASS]
depreciated_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
._.
Rentals_NN
under_IN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
even_RB
if_COND
payments_NOMZ
are_VPRT [PASS]
made_VBN
on_PIN
another_DT
basis_NN
._.
Estimates_NN
and_PHC
assumptions_NOMZ
The_DT
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
in_PIN
conformity_NOMZ
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
standards_NN
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
and_PHC
disclosures_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
as_IN
of_PIN
the_DT
dates_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
year_NN
._.
In_PIN
the_DT
preparation_NOMZ
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
estimates_NN
and_PHC
assumptions_NOMZ
have_VPRT [PEAS]
been_VBN [BYPA]
made_VBN
by_PIN
management_NOMZ
concerning_VBG [WZPRES]
the_DT
selection_NOMZ
of_PIN
useful_JJ
lives_NN
of_PIN
fixed_JJ
assets_NN
,_,
provisions_NN
necessary_JJ
for_PIN
certain_JJ
liabilities_NOMZ
,_,
the_DT
carrying_VBG
value_NN
of_PIN
investments_NOMZ
,_,
the_DT
recoverability_NOMZ
of_PIN
deferred_JJ
tax_NN
assets_NN
and_CC
other_JJ
similar_JJ
evaluations_NOMZ
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
2_CD
Turnover_NN
and_PHC
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
Turnover_NN
and_PHC
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
relate_VPRT
solely_RB
to_PIN
the_DT
principal_JJ
activity_NOMZ
and_CC
are_VPRT [BEMA]
attributable_PRED
to_PIN
the_DT
continuing_VBG
operations_NOMZ
of_PIN
the_DT
Group_NN
substantially_RB
all_QUAN
of_PIN
which_WDT [PIRE]
take_VPRT
place_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
Turnover_NN
principally_RB
consists_VPRT
of_PIN
licence_NN
fees_NN
,_,
milestone_NN
payments_NOMZ
and_PHC
fees_NN
for_PIN
research_NN
and_PHC
development_NOMZ
services_NN
provided_VBN
under_IN
corporate_JJ
agreements_NOMZ
._.
2002 2001 2000 000_CD
000_CD
000_CD
Total_JJ
turnover_NN
16,891_CD
9,421_CD
7,018_CD
Less_RB
:_:
intra-group_JJ
eliminations_NOMZ
7,420_CD
2,300_CD
Consolidated_NN
turnover_NN
9,471_CD
7,121_CD
7,018_CD
Consolidated_NN
turnover_NN
was_VBD [PASS]
generated_VBN
from_PIN
customers_NN
in_PIN
the_DT
following_VBG
geographical_JJ
areas_NN
:_:
2002 2001 2000 000_CD
000_CD
000_CD
United_NN
Kingdom_NN
316_CD
Rest_VB
of_PIN
Europe_NN
135_CD
53_CD
1,104_CD
United_NN
States_NN
of_PIN
America_NN
8,674_CD
6,969_CD
5,598_CD
Rest_VPRT
of_PIN
World_NN
662_CD
99_CD
9,471_CD
7,121_CD
7,018_CD
Net_JJ
liabilities_NOMZ
of_PIN
349,000_CD
excluding_VBG
creditors_NN
eliminated_VBN [WZPAST]
on_PIN
consolidation_NOMZ
of_PIN
9,210,000_CD
2001_CD
:_:
net_JJ
assets_NN
of_PIN
643,000_CD
,_,
excluding_VBG
creditors_NN
eliminated_VBN [WZPAST]
on_PIN
consolidation_NOMZ
of_PIN
2,387,000_CD
and_CC
total_JJ
assets_NN
of_PIN
549,000_CD
2001_CD
:_:
643,000_CD
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
47_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
2_CD
Turnover_NN
and_PHC
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
continued_VBD
Consolidated_NN
turnover_NN
by_PIN
type_NN
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Licence_NN
fees_NN
1,676_CD
1,635_CD
699_CD
Technical_NN
milestones_NN
35_CD
652_CD
Clinical_JJ
milestones_NN
1,396_CD
1,000_CD
Contract_NN
research_NN
fees_NN
5,611_CD
5,369_CD
4,536_CD
Other_JJ
753 117 131_CD
Total_JJ
9,471_CD
7,121_CD
7,018_CD
During_PIN
the_DT
financial_JJ
years_NN
ended_VBN
30_CD
September_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
certain_JJ
customers_NN
individually_RB
contributed_VBD
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
Groups_NN
revenue_NN
in_PIN
each_QUAN
year_NN
._.
The_DT
amounts_NN
of_PIN
those_DEMO
individual_JJ
contributions_NOMZ
in_PIN
order_NN
of_PIN
size_NN
by_PIN
year_NN
were_VBD
as_IN
follows_VPRT
:_:
%_NN
000_CD
2002_CD
Customer_NN
contributing_VBG [WZPRES]
greatest_JJ
%_NN
to_PIN
revenue_NN
36_CD
3,424_CD
2002_CD
Customer_NN
contributing_VBG [WZPRES]
second_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
31_CD
2,954_CD
Total_JJ
67_CD
6,378_CD
2001_CD
Customer_NN
contributing_VBG [WZPRES]
greatest_JJ
%_NN
to_PIN
revenue_NN
31_CD
2,230_CD
2001_CD
Customer_NN
contributing_VBG [WZPRES]
second_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
30_CD
2,101_CD
2001_CD
Customer_NN
contributing_VBG [WZPRES]
third_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
24_CD
1,742_CD
Total_JJ
85_CD
6,073_CD
2000_CD
Customer_NN
contributing_VBG [WZPRES]
greatest_JJ
%_NN
to_PIN
revenue_NN
37_CD
2,609_CD
2000_CD
Customer_NN
contributing_VBG [WZPRES]
second_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
20_CD
1,425_CD
2000_CD
Customer_NN
contributing_VBG [WZPRES]
third_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
15_CD
1,050_CD
2000_CD
Customer_NN
contributing_VBG [WZPRES]
fourth_JJ
greatest_JJ
%_NN
to_PIN
revenue_NN
14_CD
1,000_CD
Total_JJ
86_CD
6,084_CD
As_IN
at_PIN
30_CD
September_NN
2002_CD
,_,
the_DT
two_CD
customers_NN
shown_VBN [PRIV]
above_PLACE
constituted_VBN
89_CD
%_NN
of_PIN
the_DT
Groups_NN
trade_VPRT
receivables_NN
._.
As_IN
at_PIN
30_CD
September_NN
2001_CD
the_DT
three_CD
customers_NN
shown_VBN [PRIV]
above_PLACE
constituted_VBN
96_CD
%_NN
of_PIN
the_DT
Groups_NN
trade_VPRT
receivables_NN
._.
3_CD
Drug_NN
Royalty_NN
transaction_NOMZ
costs_NN
General_NN
and_PHC
administration_NOMZ
expenses_NN
include_VPRT
7.9_CD
million_CD
of_PIN
costs_NN
incurred_VBN [WZPAST]
in_PIN
the_DT
year_NN
relating_VBG [WZPRES]
to_PIN
the_DT
two_CD
transactions_NOMZ
entered_VBD
into_PIN
with_PIN
DRC_NN
during_PIN
the_DT
year_NN
comparative_JJ
periods_NN
:_:
none_INPR
._.
In_PIN
January_NN
2002_CD
,_,
the_DT
Group_NN
announced_VBD [PUBV]
a_DT
recommended_VBN [SUAV]
offer_NN
for_PIN
the_DT
whole_NN
of_PIN
DRC_NN
._.
A_DT
competing_VBG
offer_NN
was_VBD [BYPA]
made_VBN
by_PIN
Inwest_NN
Investments_NOMZ
Ltd_NN
of_PIN
Canada_NN
which_WDT [WHSUB]
was_VBD [PASS]
accepted_VBN [PRIV]
in_PIN
April_NN
2002_CD
._.
Under_IN
an_DT
agreement_NOMZ
with_PIN
DRC_NN
,_,
the_DT
Group_NN
received_VBD
a_DT
payment_NOMZ
of_PIN
1.5_CD
million_CD
in_PIN
1994_CD
in_PIN
return_NN
for_PIN
rights_NN
to_PIN
a_DT
percentage_NN
of_PIN
revenues_NN
and_CC
certain_JJ
other_JJ
payments_NOMZ
received_VBN [WZPAST]
by_PIN
the_DT
Group_NN
over_IN
a_DT
period_NN
terminating_VBG [WZPRES]
in_PIN
2009_CD
._.
On_PIN
2_CD
May_POMD
2002_CD
,_,
the_DT
Group_NN
bought_VBD
out_PIN
this_DEMO
royalty_NN
obligation_NOMZ
to_PIN
DRC_NN
for_PIN
consideration_NOMZ
of_PIN
6.1_CD
million_CD
CAD$_NN
14_CD
million_CD
with_PIN
the_DT
issue_NN
of_PIN
463,818_CD
CAT_NN
shares_NN
to_PIN
DRC_NN
._.
The_DT
remaining_VBG
balance_NN
of_PIN
0.6_CD
million_CD
of_PIN
deferred_JJ
income_NN
has_VPRT
all_QUAN
been_VBN [PASS]
released_VBN
to_PIN
turnover_NN
in_PIN
the_DT
period_NN
._.
The_DT
professional_JJ
fees_NN
incurred_VBN [WZPAST]
in_PIN
the_DT
Groups_NN
bid_NN
and_PHC
royalty_NN
buy-back_NN
were_VBD [BEMA]
1.8_CD
million_CD
._.
48_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
4_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
2002 2001 2000 000_CD
000_CD
000_CD
The_DT
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
crediting_VBG
:_:
Depreciation_NOMZ
and_PHC
amounts_NN
written_VBN [PUBV] [WZPAST]
off_PIN
owned_VBN
tangible_JJ
fixed_JJ
assets_NN
:_:
2,617_CD
2,146_CD
1,808_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
fixed_JJ
assets_NN
882 373 374_CD
Auditors_NN
remuneration_JJ
audit_NN
Deloitte_NN
&_CC
Touche_NN
35_CD
audit_NN
Arthur_NN
Andersen_NN
42_CD
27_CD
other_JJ
assurance_NN
Deloitte_NN
&_CC
Touche_NN
19_CD
other_JJ
Deloitte_NN
&_CC
Touche_NN
9_CD
other_JJ
Arthur_NN
Andersen_NN
287 149 219_CD
Foreign_JJ
exchange_NN
loss_NN
gain_NN
192_CD
56_CD
123_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
Denzyme_NN
ApS_NN
2_CD
Operating_GER
lease_NN
rentals_NN
:_:
plant_NN
and_PHC
machinery_NN
5_CD
33_CD
other_JJ
operating_VBG
leases_NN
874 721 290_CD
Allocations_NOMZ
under_IN
equity_NOMZ
participation_NOMZ
schemes_NN
607 416 459_CD
Arthur_NN
Andersen_NN
resigned_VBD
as_IN
auditors_NN
to_PIN
the_DT
Group_NN
on_PIN
17_CD
May_POMD
2002_CD
and_CC
were_VBD [BYPA]
replaced_VBN
by_PIN
Deloitte_NN
&_CC
Touche_NN
._.
5_CD
Interest_NN
receivable_NN
2002 2001 2000 000_CD
000_CD
000_CD
Interest_NN
receivable_NN
6,386_CD
9,295_CD
5,644_CD
6_CD
Staff_NN
costs_NN
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
persons_NN
including_VBG [WZPRES]
Executive_NN
Directors_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
:_:
2002 2001 2000_CD
Management_NOMZ
and_PHC
administration_NOMZ
39_CD
32_CD
22_CD
Research_NN
and_PHC
development_NOMZ
235 192 139 274_CD
224 161 000 000_CD
000_CD
Their_TPP3
aggregate_JJ
remuneration_NOMZ
comprised_VBN
:_:
Wages_NN
and_PHC
salaries_NN
9,771_CD
7,268_CD
5,233_CD
Social_NN
security_NOMZ
costs_NN
credit_NN
charge_NN
provided_VBN [WZPAST]
on_PIN
unapproved_JJ
options_NOMZ
248 194 523_CD
on_PIN
wages_NN
and_PHC
salaries_NN
970 740 527_CD
Other_JJ
pension_NN
costs_NN
875 641 432_CD
11,368_CD
8,455_CD
6,715_CD
Further_JJ
audited_JJ
information_NOMZ
on_PIN
Directors_NN
remuneration_NOMZ
is_VPRT [PASS]
contained_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
made_VBN
a_DT
provision_NN
for_PIN
employers_NN
National_NN
Insurance_NN
payable_JJ
on_PIN
certain_JJ
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
CSOP_NN
Part_NN
B_NN
scheme_NN
in_PIN
December_NN
1999_CD
._.
The_DT
liability_NOMZ
will_PRMD
not_XX0
crystallise_VB
until_IN
the_DT
options_NOMZ
are_VPRT [PASS]
exercised_VBN
they_TPP3
are_VPRT [BEMA]
exercisable_PRED
from_PIN
December_NN
2002_CD
and_CC
the_DT
ultimate_JJ
liability_NOMZ
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
difference_NN
between_PIN
the_DT
exercise_NN
price_NN
paid_VBN [WZPAST]
by_PIN
the_DT
employee_NN
and_CC
the_DT
market_NN
price_NN
on_PIN
exercise_NN
and_CC
on_PIN
the_DT
then_RB
prevailing_VBG
rate_NN
for_PIN
employers_NN
contributions_NOMZ
._.
49_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
6_CD
Staff_NN
costs_NN
continued_VBD
The_DT
options_NOMZ
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
the_DT
condition_NOMZ
that_TOBJ
the_DT
proportionate_NN
increase_NN
in_PIN
the_DT
closing_GER
price_NN
of_PIN
shares_NN
in_PIN
the_DT
Company_NN
over_IN
a_DT
specified_JJ
period_NN
must_NEMD
exceed_VB
the_DT
proportionate_NN
increase_NN
in_PIN
the_DT
total_JJ
return_NN
on_PIN
the_DT
FTSE_NN
All_QUAN
Share_NN
Index_NN
._.
The_DT
specified_JJ
period_NN
begins_VPRT
on_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
ends_VPRT
between_PIN
the_DT
third_JJ
and_PHC
fourth_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
provision_NN
is_VPRT
being_VBG [PASS]
made_VBN
systematically_RB
by_PIN
reference_NN
to_PIN
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
at_PIN
the_DT
balance_NN
sheet_NN
dates_NN
over_IN
the_DT
period_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
to_PIN
the_DT
end_NN
of_PIN
the_DT
performance_NN
period_NN
,_,
and_ANDC
from_PIN
that_DEMO
date_NN
to_PIN
the_DT
date_NN
of_PIN
actual_JJ
exercise_NN
the_DT
provision_NN
will_PRMD
be_VB [BYPA]
adjusted_VBN
by_PIN
reference_NN
to_PIN
changes_NN
in_PIN
market_NN
value_NN
._.
For_PIN
this_DEMO
purpose_NN
the_DT
performance_NN
period_NN
is_VPRT [PASS]
assumed_VBN [PRIV]
to_TO
be_VB [BEMA]
of_PIN
minimum_JJ
duration_NOMZ
._.
The_DT
provision_NN
and_CC
corresponding_JJ
charges_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
will_PRMD
be_VB [BYPA]
affected_VBN
by_PIN
:_:
the_DT
elapse_NN
of_PIN
performance_NN
periods_NN
:_:
the_DT
remaining_VBG
number_NN
and_PHC
option_NOMZ
price_NN
of_PIN
shares_NN
under_IN
option_NOMZ
:_:
and_ANDC
,_,
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
._.
The_DT
market_NN
price_NN
of_PIN
shares_NN
at_PIN
the_DT
year_NN
end_NN
was_VBD [BEMA]
4.64_CD
._.
If_COND
that_DEMO
price_NN
and_CC
the_DT
relevant_JJ
number_NN
of_PIN
shares_NN
under_IN
option_NOMZ
remained_VBD
unchanged_JJ
,_,
the_DT
charge_NN
for_PIN
a_DT
further_JJ
year_NN
would_PRMD
amount_VB
to_PIN
5,000_CD
._.
If_COND
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
were_VBD
to_TO
increase_VB
by_PIN
10_CD
%_NN
over_IN
that_DEMO
at_PIN
the_DT
year_NN
end_NN
,_,
the_DT
charge_NN
would_PRMD
increase_VB
by_PIN
22,000_CD
._.
7_CD
Taxation_NOMZ
2002 2001 2000 000_CD
000_CD
000_CD
Research_NN
and_PHC
development_NOMZ
tax_NN
credit_NN
3,557_CD
During_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2002_CD
the_DT
Group_NN
received_VBD
a_DT
refund_NN
of_PIN
920,000_CD
in_PIN
respect_NN
of_PIN
the_DT
surrender_NN
of_PIN
tax_NN
losses_NN
created_VBN [WZPAST]
through_PIN
research_NN
and_PHC
development_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2000_CD
._.
A_DT
similar_JJ
claim_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2001_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
other_JJ
debtors_NN
at_PIN
30_CD
September_NN
2002_CD
,_,
and_ANDC
for_PIN
which_WDT [PIRE]
the_DT
Group_NN
received_VBD
a_DT
refund_NN
of_PIN
2,637,000_CD
in_PIN
October_NN
2002_CD
._.
The_DT
tax_NN
assessed_VBN [WZPAST]
for_PIN
the_DT
year_NN
differs_VPRT
from_PIN
that_DEMP
resulting_VBG
from_PIN
applying_VBG
the_DT
standard_JJ
rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
of_PIN
30_CD
%_NN
2001_CD
:_:
30_CD
%_NN
._.
The_DT
differences_NN
are_VPRT [PASS]
explained_VBN [PUBV]
below_PLACE
:_:
2002 2001 000 000_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
31,764_CD
11,771_CD
Tax_NN
at_PIN
30_CD
%_NN
thereon_NN
9,529_CD
3,531_CD
Effects_NN
of_PIN
:_:
Increase_VB
in_PIN
losses_NN
carried_VBD
forward_RB
11,400_CD
5,071_CD
Expenses_NN
not_XX0
deductible_JJ
for_PIN
tax_NN
purposes_NN
1,041_CD
1,205_CD
Capital_NN
allowances_NN
in_PIN
excess_NN
of_PIN
depreciation_NOMZ
888_CD
335_CD
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
in_PIN
respect_NN
of_PIN
research_NN
and_PHC
development_NOMZ
tax_NN
credit_NN
3,557_CD
Movement_NOMZ
in_PIN
short_JJ
term_NN
timing_NN
differences_NN
58_CD
3,557_CD
Analysis_NN
of_PIN
deferred_JJ
tax_NN
balances_NN
:_:
2002 2001 000 000_CD
Short_JJ
term_NN
timing_NN
differences_NN
58_CD
Accelerated_VBN
capital_NN
allowances_NN
1,272_CD
335_CD
Tax_NN
losses_NN
available_JJ
23,658_CD
18,126_CD
Total_JJ
unprovided_JJ
deferred_JJ
tax_NN
asset_NN
22,444_CD
18,461_CD
At_PIN
30_CD
September_NN
2002_CD
the_DT
Group_NN
had_VBD
tax_NN
losses_NN
of_PIN
approximately_RB
79_CD
million_CD
2001_CD
:_:
60_CD
million_CD
,_,
2000_CD
:_:
36_CD
million_CD
available_JJ
for_PIN
relief_NN
against_PIN
future_JJ
taxable_JJ
profits_NN
._.
Due_JJ
to_PIN
the_DT
availability_NOMZ
of_PIN
tax_NN
losses_NN
there_EX
is_VPRT
no_SYNE
provision_NN
for_PIN
deferred_VBN
taxation_NOMZ
._.
A_DT
deferred_JJ
tax_NN
asset_NN
amounting_VBG [WZPRES]
to_PIN
24_CD
million_CD
representing_VBG
such_JJ
losses_NN
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
The_DT
deferred_JJ
tax_NN
asset_NN
would_PRMD
become_VB
recoverable_JJ
should_NEMD
the_DT
Group_NN
generate_VB
relevant_JJ
taxable_JJ
profits_NN
against_PIN
which_WDT [PIRE]
the_DT
tax_NN
losses_NN
would_PRMD
be_VB [PASS]
offset_VBN
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
19_CD
Deferred_NN
Tax_NN
by_PIN
the_DT
Group_NN
has_VPRT
no_SYNE
effect_NN
on_PIN
prior_JJ
periods_NN
._.
50_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
8_CD
Loss_NN
per_PIN
share_NN
Basic_JJ
net_JJ
loss_NN
per_PIN
share_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
net_JJ
loss_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
._.
The_DT
computation_NOMZ
of_PIN
diluted_JJ
net_JJ
loss_NN
per_PIN
share_NN
reflects_VPRT [PRIV]
the_DT
potential_JJ
dilution_NOMZ
that_TSUB
could_POMD
occur_VB
if_COND
dilutive_JJ
securities_NOMZ
and_CC
other_JJ
contracts_NN
to_TO
issue_VB
ordinary_JJ
shares_NN
were_VBD [PASS]
exercised_VBN
or_CC
converted_VBN
into_PIN
ordinary_JJ
shares_NN
or_CC
resulted_VBD
in_PIN
the_DT
issue_NN
of_PIN
ordinary_JJ
shares_NN
that_TSUB
then_RB
shared_VBD
in_PIN
the_DT
net_JJ
loss_NN
of_PIN
the_DT
Group_NN
._.
Potentially_RB
dilutive_JJ
issuable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
calculation_NOMZ
of_PIN
diluted_JJ
loss_NN
per_PIN
share_NN
if_COND
their_TPP3
issue_NN
would_PRMD
increase_VB
net_JJ
loss_NN
per_PIN
share_NN
or_CC
decrease_NN
net_JJ
profit_NN
per_PIN
share_NN
._.
Since_OSUB
the_DT
Group_NN
has_VPRT [PEAS]
reported_VBN [PUBV]
losses_NN
,_,
its_PIT
basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
share_NN
are_VPRT [BEMA]
therefore_CONJ
equal_PRED
._.
For_PIN
the_DT
years_NN
ending_VBG [WZPRES]
30_CD
September_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
867,316_CD
,_,
1,077,800_CD
and_CC
1,548,764_CD
potentially_RB
dilutive_JJ
issuable_JJ
shares_NN
attributable_JJ
to_PIN
the_DT
exercise_NN
of_PIN
outstanding_JJ
options_NOMZ
were_VBD [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
diluted_JJ
loss_NN
per_PIN
share_NN
._.
No_SYNE
adjustments_NOMZ
were_VBD [PASS]
made_VBN
to_TO
reported_VBN [PUBV]
net_JJ
loss_NN
in_PIN
the_DT
computation_NOMZ
of_PIN
net_JJ
loss_NN
per_PIN
share_NN
._.
11_CD
Fixed_JJ
asset_NN
investments_NOMZ
Group_NN
Company_NN
Other_JJ
Subsidiary_NN
investments_NOMZ
undertakings_GER
000_CD
000_CD
Cost_NN
and_CC
net_JJ
book_NN
value_NN
At_PIN
1_CD
October_NN
2001_CD
101,456_CD
Additions_NOMZ
215_CD
At_PIN
30_CD
September_NN
2002 215 101_CD
,456_CD
The_DT
subsidiary_NN
undertakings_GER
of_PIN
the_DT
Company_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
consolidated_PRED
,_,
are_VPRT
as_IN
follows_VPRT
:_:
Country_NN
of_PIN
incorporation_NOMZ
Principal_NN
Percentage_NN
of_PIN
and_CC
operation_NOMZ
activity_NOMZ
ordinary_JJ
shares_NN
held_VBD [PRIV]
Cambridge_NN
Antibody_NN
Technology_NN
Limited_NN
England_NN
Research_NN
and_PHC
development_NOMZ
100_CD
%_NN
CAT_NN
Group_NN
EmployeesTrustees_NN
Limited_NN
England_NN
Share_NN
scheme_NN
trust_NN
company_NN
100_CD
%_NN
Optein_NN
Inc._NN
trading_GER
as_IN
Aptein_NN
Inc._NN
._.
USA_NN
Research_NN
and_PHC
development_NOMZ
100_CD
%_NN
During_PIN
the_DT
period_NN
the_DT
Group_NN
disposed_VBD
of_PIN
its_PIT
wholly_RB
owned_VBN
subsidiary_NN
,_,
Denzyme_NN
ApS_NN
,_,
in_PIN
return_NN
for_PIN
a_DT
minority_NOMZ
interest_NN
in_PIN
another_DT
company_NN
._.
This_DEMO
transaction_NOMZ
has_VPRT
no_SYNE
material_NN
impact_NN
on_PIN
reported_VBN [PUBV]
results_NN
._.
52_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
12_CD
Debtors_NN
Group_NN
Group_NN
Company_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Due_JJ
within_PIN
one_CD
year_NN
:_:
Trade_NN
debtors_NN
12_CD
732_CD
Due_JJ
from_PIN
subsidiary_NN
undertakings_GER
90_CD
88_CD
Other_JJ
debtors_NN
3,982_CD
386_CD
18_CD
143_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
2,562_CD
3,822_CD
1,519_CD
2,691_CD
6,556_CD
4,940_CD
1,627_CD
2,922_CD
13_CD
Investment_NOMZ
in_PIN
liquid_JJ
resources_NN
Group_NN
Group_NN
Company_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Negotiable_JJ
securities_NOMZ
:_:
Floating_VBG
rate_NN
notes_NN
24,998_CD
14,285_CD
24,998_CD
14,285_CD
Certificates_NN
of_PIN
deposit_NN
98,000_CD
128,498_CD
98,000_CD
128,498_CD
Term_NN
deposits_NN
3,696_CD
13,445_CD
2,128_CD
12,520_CD
126,694_CD
156,228_CD
125,126_CD
155,303_CD
The_DT
Group_NN
holds_VPRT [PRIV]
cash_NN
which_WDT [WHSUB]
is_VPRT
surplus_NN
to_PIN
current_JJ
requirements_NOMZ
,_,
but_CC
which_WDT
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
finance_VB
future_JJ
operations_NOMZ
,_,
in_PIN
sterling_GER
in_PIN
interest_NN
bearing_GER
marketable_JJ
securities_NOMZ
as_IN
described_VBN
in_PIN
note_NN
16_CD
._.
14_CD
Creditors_NN
Group_NN
Group_NN
Company_NN
Company_NN
2002 2001 2002 2001_CD
000 000 000 000_CD
Amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
:_:
Bank_NN
overdraft_NN
163_CD
Trade_NN
creditors_NN
3,999_CD
727_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiary_NN
undertakings_GER
1,194_CD
43,350_CD
Taxation_NOMZ
and_CC
social_JJ
security_NOMZ
304_CD
Other_JJ
creditors_NN
1,003_CD
534_CD
Accruals_NN
i_FPP1
4,710_CD
3,953_CD
48_CD
45_CD
Deferred_JJ
income_NN
2,547_CD
2,958_CD
12,563_CD
8,335_CD
1,242_CD
43,395_CD
i_FPP1
Includes_VPRT
purchase_NN
commitments_NOMZ
of_PIN
888,000_CD
2001_CD
:_:
101,000_CD
._.
The_DT
bank_NN
overdraft_NN
comprised_VBD
payments_NOMZ
to_PIN
suppliers_NN
and_CC
other_JJ
third_JJ
parties_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
in_PIN
the_DT
course_NN
of_PIN
presentation_NOMZ
._.
15_CD
Creditors_NN
Group_NN
Group_NN
2002 2001 000 000_CD
Amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
:_:
Deferred_JJ
income_NN
8,580_CD
8,085_CD
53_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
16_CD
Financial_NN
instruments_NOMZ
The_DT
financial_JJ
instruments_NOMZ
of_PIN
the_DT
Group_NN
comprise_VPRT
cash_NN
,_,
liquid_JJ
resources_NN
and_PHC
debtors_NN
and_PHC
creditors_NN
arising_VBG [WZPRES]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
trade_VB
in_PIN
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
._.
The_DT
Groups_NN
liquid_JJ
resources_NN
are_VPRT [PASS]
managed_VBN
on_PIN
a_DT
discretionary_JJ
basis_NN
by_PIN
a_DT
third_JJ
party_NN
._.
The_DT
mandate_NN
under_IN
which_WDT
the_DT
fund_NN
managers_NN
operate_VPRT
includes_VPRT
the_DT
following_VBG
criteria_NN
:_:
Investments_NOMZ
only_DWNT
in_PIN
freely_RB
negotiable_JJ
instruments_NOMZ
or_CC
deposits_NN
with_PIN
specified_VBN
banks_NN
and_PHC
building_GER
societies_NN
._.
For_PIN
the_DT
whole_JJ
fund_NN
,_,
limits_NN
on_PIN
the_DT
maximum_NN
exposure_NN
to_PIN
counterparties_NN
with_PIN
particular_JJ
minimum_JJ
credit_NN
ratings_GER
,_,
which_WDT [SERE]
ratings_GER
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
deliberately_RB
high_JJ
._.
For_PIN
investments_NOMZ
in_CONJ
particular_NULL
classes_NN
of_PIN
instrument_NOMZ
,_,
minimum_JJ
credit_NN
ratings_GER
which_WDT [WHSUB]
are_VPRT [BEMA]
tighter_PRED
than_PIN
for_PIN
the_DT
fund_NN
as_IN
a_DT
whole_JJ
or_CC
an_DT
agreed_VBN [SUAV] [PUBV]
counterparty_NN
list_NN
._.
For_PIN
the_DT
whole_JJ
fund_NN
,_,
a_DT
maturity_NOMZ
profile_NN
which_WDT [WHSUB]
is_VPRT [PASS]
tailored_VBN
to_PIN
the_DT
Groups_NN
expected_VBN [PRIV]
cash_NN
requirements_NOMZ
as_IN
investments_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
to_PIN
maturity_NOMZ
._.
No_SYNE
currency_NN
exposure_NN
or_CC
short_JJ
positions_NOMZ
._.
These_DEMO
criteria_NN
are_VPRT [BYPA]
set_VBN
by_PIN
the_DT
Board_NN
and_CC
are_VPRT [PASS]
reviewed_VBN
when_RB
deemed_VBN [PRIV]
necessary_JJ
._.
The_DT
principal_JJ
purpose_NN
of_PIN
the_DT
Groups_NN
liquid_JJ
resources_NN
is_VPRT [BEMA]
for_PIN
future_JJ
funding_GER
and_ANDC
hence_CONJ
their_TPP3
safeguarding_VBG
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
greater_JJ
priority_NOMZ
than_PIN
the_DT
actual_JJ
return_NN
made_VBN [WZPAST]
on_PIN
the_DT
investments_NOMZ
._.
The_DT
criteria_NN
for_PIN
fund_NN
management_NOMZ
reflect_VPRT [PRIV] [THATD]
this_DEMP
._.
The_DT
Audit_NN
Committee_NN
review_NN
the_DT
return_NN
made_VBN [WZPAST]
on_PIN
the_DT
Groups_NN
funds_NN
against_PIN
benchmark_JJ
market_NN
returns_NN
quarterly_RB
._.
The_DT
majority_NOMZ
of_PIN
the_DT
Groups_NN
investments_NOMZ
are_VPRT [BEMA]
short_JJ
term_NN
investments_NOMZ
and_ANDC
hence_CONJ
exposure_NN
to_PIN
interest_NN
rate_NN
changes_NN
has_VPRT [PEAS]
been_VBN [BEMA]
minimal_PRED
._.
Realisation_NOMZ
of_PIN
losses_NN
from_PIN
interest_NN
rate_NN
movements_NOMZ
is_VPRT [BEMA]
unlikely_PRED
as_IN
investments_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
to_PIN
maturity_NOMZ
._.
Declines_NN
in_PIN
interest_NN
rates_NN
over_IN
time_NN
will_PRMD
,_,
however_CONJ
,_,
reduce_VB
the_DT
Groups_NN
interest_NN
income_NN
._.
The_DT
results_NN
of_PIN
the_DT
Group_NN
have_VPRT
not_XX0
,_,
to_PIN
date_NN
,_,
been_VBN [PASTP] [SPAU] [BYPA]
materially_RB
impacted_VBN
by_PIN
exchange_NN
rate_NN
fluctuations_NOMZ
._.
However_CONJ
,_,
a_DT
significant_JJ
proportion_NOMZ
of_PIN
current_JJ
and_PHC
future_JJ
income_NN
is_VPRT [BEMA]
likely_PRED
to_TO
be_VB [BEMA]
receivable_PRED
in_PIN
United_NN
States_NN
Dollars_NN
which_WDT [WHSUB]
may_POMD
give_VB
rise_VB
to_PIN
transactional_JJ
currency_NN
exposures_NN
due_JJ
to_PIN
fluctuations_NOMZ
in_PIN
the_DT
exchange_NN
rate_NN
between_PIN
United_NN
States_NN
Dollars_NN
and_PHC
Sterling_GER
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
Groups_NN
functional_JJ
currency_NN
._.
Where_RB
possible_JJ
,_,
the_DT
Group_NN
seeks_VPRT
to_TO
match_VB
United_NN
States_NN
Dollar_NN
income_NN
with_PIN
United_NN
States_NN
Dollar_NN
expenditure_NN
._.
To_TO
date_VB
the_DT
Group_NN
has_VPRT [PEAS]
not_XX0
hedged_VBN
any_QUAN
transactional_JJ
currency_NN
exposure_NN
but_CC
will_PRMD
keep_VB
such_JJ
exposures_NN
under_IN
review_NN
and_ANDC
where_RB
prudent_JJ
and_PHC
appropriate_JJ
may_POMD
enter_VB
into_PIN
such_JJ
transactions_NOMZ
in_PIN
future_NN
._.
Financial_NN
Fixed_NN
rate_NN
Floating_VBG [WZPRES]
rate_NN
liabilities_NOMZ
financial_JJ
financial_JJ
on_PIN
which_WDT [PIRE]
no_SYNE
assets_NN
i_FPP1
assets_NN
ii_FW
interest_NN
is_VPRT [PASS]
paid_VBN
Total_NN
Financial_NN
assets_NN
and_PHC
liabilities_NOMZ
000 000 000 000_CD
At_PIN
30_CD
September_NN
2002_CD
Sterling_GER
assets_NN
liabilities_NOMZ
11,998_CD
114,699_CD
1,678_CD
125,019_CD
United_NN
States_NN
Dollar_NN
assets_NN
4,755_CD
4,755_CD
Other_JJ
assets_NN
1_CD
1_CD
Book_NN
value_NN
11,998_CD
119,455_CD
1,678_CD
129,775_CD
Fair_NN
value_NN
12,000_CD
119,563_CD
1,678_CD
129,885_CD
i_FPP1
Interest_NN
rates_NN
determined_VBD [SUAV] [PRIV]
for_PIN
more_EMPH
than_PIN
one_CD
year_NN
._.
ii_FW
Interest_NN
rates_NN
determined_VBD [SUAV] [PRIV]
at_PIN
least_JJ
once_TIME
a_DT
year_NN
._.
54_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
16_CD
Financial_NN
instruments_NOMZ
continued_VBD
Financial_JJ
Fixed_JJ
rate_NN
Floating_VBG [WZPRES]
rate_NN
liabilities_NOMZ
financial_JJ
financial_JJ
on_PIN
which_WDT [PIRE]
no_SYNE
assets_NN
i_FPP1
assets_NN
ii_FW
interest_NN
is_VPRT [PASS]
paid_VBN
Total_NN
Financial_NN
assets_NN
and_PHC
liabilities_NOMZ
000 000 000 000_CD
At_PIN
30_CD
September_NN
2001_CD
Sterling_GER
assets_NN
liabilities_NOMZ
8,498_CD
147,731_CD
1,346_CD
154,883_CD
United_NN
States_NN
Dollar_NN
assets_NN
1,760_CD
1,760_CD
Other_JJ
assets_NN
77_CD
Book_NN
value_NN
8,498_CD
149,498_CD
1,346_CD
156,650_CD
Fair_NN
value_NN
8,966_CD
151,943_CD
1,346_CD
159,563_CD
i_FPP1
Interest_NN
rates_NN
determined_VBD [SUAV] [PRIV]
for_PIN
more_EMPH
than_PIN
one_CD
year_NN
._.
The_DT
weighted_JJ
average_JJ
return_NN
on_PIN
the_DT
fixed_JJ
rate_NN
financial_JJ
assets_NN
was_VBD [BEMA]
3.1_CD
%_NN
2001_CD
:_:
6.1_CD
%_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
fixed_VBN
over_IN
a_DT
weighted_JJ
average_JJ
term_NN
of_PIN
1.3_CD
years_NN
2001_CD
:_:
1.5_CD
years_NN
._.
The_DT
returns_NN
achieved_VBN [WZPAST]
on_PIN
fixed_VBN
and_PHC
floating_VBG
rate_NN
financial_JJ
assets_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
money_NN
market_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
a_DT
transaction_NOMZ
is_VPRT [PASS]
entered_VBN
into_PIN [STPR]
._.
In_PIN
this_DEMO
disclosure_NN
financial_JJ
assets_NN
comprise_VPRT
liquid_JJ
resources_NN
and_PHC
cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
._.
Short_JJ
term_NN
debtors_NN
and_PHC
creditors_NN
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
._.
The_DT
financial_JJ
liabilities_NOMZ
on_PIN
which_WDT [PIRE]
no_SYNE
interest_NN
is_VPRT [PASS]
paid_VBN
comprise_VPRT
payments_NOMZ
to_PIN
third_JJ
parties_NN
in_PIN
the_DT
course_NN
of_PIN
presentation_NOMZ
._.
These_DEMP
are_VPRT [BEMA]
payable_PRED
on_PIN
demand_NN
._.
The_DT
Directors_NN
do_VPRT
not_XX0
consider_VB [PRIV]
the_DT
deferred_JJ
income_NN
balances_NN
to_TO
be_VB [BEMA]
financial_JJ
liabilities_NOMZ
where_RB
monies_NN
received_VBN [WZPAST]
are_VPRT [BEMA]
non-refundable_PRED
._.
Fair_NN
value_NN
of_PIN
marketable_JJ
securities_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
market_NN
value_NN
._.
Currency_NN
exposures_NN
At_PIN
the_DT
year_NN
end_NN
the_DT
Groups_NN
individual_JJ
operations_NOMZ
had_VBD
the_DT
following_JJ
net_JJ
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
currencies_NN
other_JJ
than_PIN
their_TPP3
functional_JJ
currency_NN
._.
USD_NN
Sterling_GER
Other_JJ
Total_NN
000 000 000 000_CD
At_PIN
30_CD
September_NN
2002_CD
Functional_JJ
currency_NN
:_:
Sterling_GER
801_CD
87_CD
714_CD
United_NN
States_NN
Dollar_NN
90_CD
90_CD
801_CD
90_CD
87_CD
624_CD
USD_NN
Sterling_GER
Other_JJ
Total_NN
000 000 000 000_CD
At_PIN
30_CD
September_NN
2001_CD
Functional_JJ
currency_NN
:_:
Sterling_GER
30_CD
2_CD
28_CD
United_NN
States_NN
Dollar_NN
88_CD
88_CD
30_CD
88_CD
2_CD
60_CD
Transactions_NOMZ
in_PIN
such_JJ
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
give_VPRT
rise_NN
to_PIN
currency_NN
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
55_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
17_CD
Called-up_JJ
share_NN
capital_NN
and_PHC
share_NN
premium_NN
2002_CD
2001_CD
Authorised_VBN
000_CD
000_CD
50,000,000_CD
2001_CD
:_:
50,000,000_CD
ordinary_JJ
shares_NN
of_PIN
10p_JJ
each_QUAN
5,000_CD
5,000_CD
During_PIN
the_DT
year_NN
the_DT
Directors_NN
exercised_VBN
their_TPP3
powers_NN
to_TO
allot_VB
ordinary_JJ
shares_NN
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
._.
10p_JJ
ordinary_JJ
Issued_VBN
Share_NN
shares_NN
share_VPRT
capital_NN
premium_NN
Allotted_NN
,_,
called-up_JJ
and_CC
fully_AMP
paid_VBN
Number_NN
000_CD
000_CD
At_PIN
1_CD
October_NN
2001_CD
35,455,865_CD
3,546_CD
195,017_CD
Issued_VBN
to_PIN
the_DT
Share_NN
Incentive_NN
Plan_NN
36,838_CD
4_CD
623_CD
Exercise_NN
of_PIN
options_NOMZ
251,634_CD
25_CD
755_CD
Exercise_NN
of_PIN
options_NOMZ
i_FPP1
4,000_CD
In_PIN
lieu_NN
of_PIN
fees_NN
ii_FW
2,194_CD
37_CD
To_PIN
Drug_NN
Royalty_NN
Corporation_NOMZ
as_IN
part_NN
of_PIN
the_DT
termination_NOMZ
of_PIN
the_DT
royalty_NN
agreement_NOMZ
iii_FW
463,818_CD
46_CD
6,102_CD
At_PIN
30_CD
September_NN
2002_CD
36,214,349_CD
3,621_CD
202,534_CD
i_FPP1
Exercised_VBN
over_IN
shares_NN
in_PIN
CAT_NN
Limited_NN
and_CC
exchanged_VBD
._.
Issued_VBN [PASTP]
at_PIN
an_DT
aggregate_JJ
premium_NN
of_PIN
5,000_CD
._.
ii_FW
All_QUAN
Non-Executive_JJ
Directors_NN
elected_VBN
to_TO
take_VB
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
shares_NN
._.
iii_FW
Shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
price_NN
of_PIN
13.26_CD
per_PIN
share_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
average_JJ
share_NN
price_NN
for_PIN
the_DT
ten_CD
days_NN
prior_RB
to_PIN
30_CD
April_NN
2002_CD
._.
At_PIN
30_CD
September_NN
2002_CD
options_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
over_IN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
._.
Options_NOMZ
also_RB
exist_VPRT
over_IN
shares_NN
in_PIN
CAT_NN
Limited_NN
which_WDT [WHSUB]
are_VPRT [PASS]
matched_VBN
with_PIN
share_NN
exchange_NN
option_NOMZ
agreements_NOMZ
whereby_OSUB
shares_NN
allotted_VBN [WZPAST]
in_PIN
CAT_NN
Limited_NN
on_PIN
exercise_NN
are_VPRT [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
shares_NN
in_PIN
the_DT
Company_NN
._.
The_DT
tabulation_NOMZ
of_PIN
options_NOMZ
below_PLACE
reflects_VPRT [PRIV]
the_DT
effective_JJ
numbers_NN
and_PHC
exercise_NN
prices_NN
of_PIN
options_NOMZ
over_IN
shares_NN
in_PIN
the_DT
Company_NN
._.
Certain_JJ
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
in_PIN
one_CD
scheme_NN
in_PIN
parallel_NN
with_PIN
options_NOMZ
in_PIN
a_DT
different_JJ
scheme_NN
under_IN
arrangements_NOMZ
whereby_OSUB
the_DT
exercise_NN
of_PIN
options_NOMZ
in_PIN
one_CD
scheme_NN
would_PRMD
cause_VB
a_DT
corresponding_JJ
number_NN
of_PIN
options_NOMZ
to_PIN
lapse_NN
in_PIN
the_DT
other_JJ
scheme_NN
._.
Where_RB
relevant_JJ
,_,
pairs_NN
of_PIN
linked_VBN
options_NOMZ
are_VPRT [PASS]
counted_VBN
as_IN
a_DT
single_JJ
option_NOMZ
._.
ii_FW
These_DEMO
options_NOMZ
were_VBD [BEMA]
subject_PRED
to_PIN
the_DT
condition_NOMZ
as_IN
stated_VBN [PUBV]
in_PIN
note_NN
iii_NN
below_PLACE
._.
This_DEMO
condition_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
satisfied_VBN
as_IN
at_PIN
30_CD
September_NN
2002_CD
._.
iii_FW
These_DEMO
options_NOMZ
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
the_DT
condition_NOMZ
that_TOBJ
the_DT
proportionate_NN
increase_NN
in_PIN
the_DT
closing_GER
price_NN
of_PIN
shares_NN
in_PIN
the_DT
Company_NN
over_IN
a_DT
specified_JJ
period_NN
must_NEMD
exceed_VB
the_DT
increase_NN
in_PIN
the_DT
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
for_PIN
the_DT
FTSE_NN
All_QUAN
Share_NN
Index_NN
._.
In_PIN
certain_JJ
circumstances_NN
,_,
such_JJ
as_IN
the_DT
death_NN
of_PIN
an_DT
employee_NN
,_,
the_DT
rules_NN
of_PIN
the_DT
CSOP_NN
permit_VPRT
the_DT
Directors_NN
to_TO
allow_VB [SUAV]
options_NOMZ
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
but_CC
which_WDT
have_VPRT [PEAS]
not_XX0
vested_VBN
to_TO
be_VB [PASS]
exercised_VBN
provided_VBD
the_DT
exercise_NN
takes_VPRT
place_NN
within_PIN
the_DT
period_NN
prescribed_VBN [WZPAST]
in_PIN
the_DT
CSOP_NN
rules_NN
in_PIN
relation_NOMZ
to_PIN
these_DEMO
circumstances_NN
._.
iv_NN
The_DT
number_NN
of_PIN
options_NOMZ
which_WDT [WHSUB]
will_PRMD
become_VB
exercisable_JJ
will_PRMD
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
a_DT
linear_JJ
sliding_VBG
scale_NN
on_PIN
the_DT
third_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
based_VBN [WZPAST]
on_PIN
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
TSR_NN
for_PIN
the_DT
Company_NN
exceeds_VPRT
the_DT
percentage_NN
increase_NN
in_PIN
the_DT
TSR_NN
for_PIN
the_DT
FTSE_NN
All_QUAN
Share_NN
Index_NN
by_PIN
an_DT
amount_NN
of_PIN
between_PIN
0_CD
%_NN
and_CC
33_CD
%_NN
._.
57_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
18_CD
Profit_NN
and_PHC
loss_NN
account_NN
and_CC
other_JJ
reserve_NN
Group_NN
Group_NN
Company_NN
Profit_NN
Other_JJ
Profit_NN
and_PHC
loss_NN
reserve_NN
and_PHC
loss_NN
000 000 000_CD
At_PIN
1_CD
October_NN
2001_CD
55,964_CD
13,451_CD
17,725_CD
Retained_VBN
loss_NN
profit_NN
for_PIN
the_DT
year_NN
28,207_CD
3,090_CD
Premium_NN
on_PIN
issue_NN
of_PIN
capital_NN
in_PIN
subsidiary_NN
5_CD
Foreign_NN
exchange_NN
translation_NOMZ
96_CD
Write_VPRT [PUBV]
back_RB
of_PIN
goodwill_NN
on_PIN
sale_NN
of_PIN
Denzyme_NN
ApS_NN
229_CD
At_PIN
30_CD
September_NN
2002_CD
83,846_CD
13,456_CD
20,815_CD
The_DT
other_JJ
reserve_NN
represents_VPRT
the_DT
share_NN
premium_NN
account_NN
of_PIN
CAT_NN
Limited_NN
and_CC
arises_VPRT
on_PIN
consolidation_NOMZ
from_PIN
the_DT
application_NOMZ
of_PIN
merger_NN
accounting_GER
principles_NN
to_PIN
the_DT
acquisition_NOMZ
of_PIN
that_DEMO
company_NN
._.
The_DT
cumulative_JJ
amount_NN
of_PIN
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
against_PIN
the_DT
Groups_NN
reserves_NN
is_VPRT [BEMA]
nil_PRED
2001_CD
:_:
229,000_CD
._.
19_CD
Reconciliation_NOMZ
of_PIN
movements_NOMZ
in_PIN
Group_NN
shareholders_NN
funds_NN
2002 2001 000 000_CD
Loss_NN
for_PIN
the_DT
financial_JJ
year_NN
28,207_CD
11,771_CD
Other_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
year_NN
325_CD
1_CD
27,882_CD
11,770_CD
New_NN
shares_NN
issued_VBD
7,597_CD
15,380_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
shareholders_NN
funds_NN
20,285_CD
3,610_CD
Opening_GER
shareholders_NN
funds_NN
156,050_CD
152,440_CD
Closing_GER
shareholders_NN
funds_NN
135,765_CD
156,050_CD
20_CD
Reconciliation_NOMZ
of_PIN
operating_VBG
loss_NN
to_TO
operating_VBG
cash_NN
flows_NN
2002 2001 2000 000_CD
000_CD
000_CD
Operating_GER
loss_NN
38,150_CD
21,066_CD
13,933_CD
Depreciation_NOMZ
charge_NN
2,617_CD
2,146_CD
1,808_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
882 373 374_CD
Loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
fixed_JJ
assets_NN
1_CD
5_CD
Shares_NN
issued_VBN
to_TO
buy_VB
out_PIN
DRC_NN
royalty_NN
agreement_NOMZ
6,149_CD
Increase_VPRT
in_PIN
debtors_NN
158_CD
515_CD
1,159_CD
Increase_VPRT
decrease_NN
in_PIN
creditors_NN
1,852_CD
89_CD
9,306_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
operating_VBG
activities_NOMZ
26,808_CD
19,150_CD
3,609_CD
58_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
21_CD
Analysis_NN
of_PIN
cash_NN
flows_NN
2002 2001 2000 000_CD
000_CD
000_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
Interest_NN
received_VBD
7,558_CD
8,322_CD
4,245_CD
Net_JJ
cash_NN
inflow_NN
7,558_CD
8,322_CD
4,245_CD
Taxation_NOMZ
Research_NN
and_PHC
development_NOMZ
tax_NN
credit_NN
received_VBN
920_CD
Net_JJ
cash_NN
inflow_NN
920_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
Purchase_NN
of_PIN
intangible_JJ
assets_NN
2,067_CD
Purchase_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
7,894_CD
3,485_CD
1,018_CD
Proceeds_NN
from_PIN
the_DT
sale_NN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
444_CD
Net_JJ
cash_NN
outflow_NN
9,961_CD
3,481_CD
974_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
Decrease_NN
increase_NN
in_PIN
term_NN
deposits_NN
9,749_CD
10,762_CD
23,980_CD
Net_JJ
sale_NN
purchase_NN
of_PIN
securities_NOMZ
19,785_CD
10,488_CD
109,749_CD
Net_JJ
cash_NN
inflow_NN
outflow_NN
29,534_CD
274_CD
133,729_CD
Financing_GER
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
1,448_CD
15,380_CD
132,302_CD
Capital_NN
elements_NOMZ
of_PIN
finance_NN
lease_NN
rental_JJ
payments_NOMZ
9_CD
Net_JJ
cash_NN
inflow_NN
1,448_CD
15,380_CD
132,293_CD
Liquid_NN
resources_NN
comprise_VPRT
current_JJ
asset_NN
investments_NOMZ
in_PIN
negotiable_JJ
securities_NOMZ
and_PHC
cash_NN
deposits_NN
._.
22_CD
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
funds_NN
1_CD
October_NN
Exchange_NN
30_CD
September_NN
2001_CD
Cash_NN
flow_NN
movement_NOMZ
2002 000 000 000_CD
000_CD
Cash_NN
at_PIN
bank_NN
585_CD
2,528_CD
32_CD
3,081_CD
Overdrafts_NN
163_CD
163_CD
2,691_CD
32_CD
Liquid_NN
resources_NN
156,228_CD
29,534_CD
126,694_CD
Net_JJ
funds_NN
156,650_CD
26,843_CD
32_CD
129,775_CD
59_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
22_CD
Analysis_NN
and_PHC
reconciliation_NOMZ
of_PIN
net_JJ
funds_NN
continued_VBD
2002 2001 2000 000_CD
000_CD
000_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
2,691_CD
1,345_CD
1,774_CD
Decrease_NN
increase_NN
in_PIN
liquid_JJ
resources_NN
29,534_CD
274_CD
133,729_CD
Decrease_NN
in_PIN
lease_NN
financing_GER
9_CD
Change_NN
in_PIN
net_JJ
funds_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
26,843_CD
1,071_CD
131,964_CD
Exchange_NN
movement_NOMZ
32_CD
2_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
in_PIN
year_NN
26,875_CD
1,071_CD
131,966_CD
Net_JJ
funds_NN
at_PIN
1_CD
October_NN
2001_CD
156,650_CD
155,579_CD
23,613_CD
Net_JJ
funds_NN
at_PIN
30_CD
September_NN
2002_CD
129,775_CD
156,650_CD
155,579_CD
23_CD
Financial_NN
commitments_NOMZ
Capital_NN
commitments_NOMZ
of_PIN
the_DT
Group_NN
were_VBD
as_IN
follows_VPRT
:_:
Group_NN
Group_NN
2002 2001 000 000_CD
Contracted_VBN
but_CC
not_XX0
provided_VBN
for_PIN
515_CD
827_CD
Since_OSUB
the_DT
end_NN
of_PIN
the_DT
2002_CD
financial_JJ
year_NN
the_DT
Group_NN
has_VPRT [PEAS]
established_VBN [PRIV] [THATD]
a_DT
finance_NN
leasing_VBG [WZPRES]
facility_NOMZ
._.
Furniture_NN
and_PHC
equipment_NOMZ
with_PIN
a_DT
cost_NN
of_PIN
504,000_CD
have_VPRT [PEAS]
been_VBN [PASS]
financed_VBN
under_IN
this_DEMO
facility_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
repayable_PRED
over_IN
four_CD
years_NN
._.
In_PIN
the_DT
next_JJ
year_NN
the_DT
Group_NN
has_VPRT
operating_VBG
lease_NN
commitments_NOMZ
as_IN
follows_VPRT
,_,
categorised_VBN [PASTP]
by_PIN
period_NN
to_TO
expiry_VB
._.
Land_NN
and_PHC
Land_NN
and_PHC
buildings_GER
Other_JJ
buildings_GER
Other_JJ
2002 2002 2001 2001_CD
000 000 000 000_CD
Expiry_NN
date_NN
:_:
within_PIN
one_CD
year_NN
2_CD
between_PIN
two_CD
and_CC
five_CD
years_NN
48_CD
1_CD
after_IN
five_CD
years_NN
1,801_CD
836_CD
The_DT
Company_NN
had_VBD
no_SYNE
capital_NN
or_CC
operating_GER
lease_NN
commitments_NOMZ
._.
24_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
operates_VPRT
a_DT
group_NN
personal_JJ
pension_NN
plan_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
a_DT
defined_VBN
contribution_NOMZ
plan_NN
._.
60_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
25_CD
Related_VBN
party_NN
transactions_NOMZ
During_PIN
the_DT
2000_CD
financial_JJ
year_NN
CAT_NN
Limited_NN
paid_VBD
a_DT
fee_NN
of_PIN
US$_$
1.3_CD
million_CD
to_PIN
Prudential_NN
Vector_NN
Healthcare_NN
Group_NN
Prudential_NN
Vector_NN
under_IN
an_DT
arrangement_NOMZ
whereby_OSUB
Prudential_NN
Vector_NN
agreed_VBD [SUAV] [PUBV]
to_TO
provide_VB
certain_JJ
financial_JJ
advisory_JJ
services_NN
._.
The_DT
arrangement_NOMZ
was_VBD [SPAU] [PASS]
subsequently_TIME
terminated_VBN
although_CONC
Prudential_NN
Vector_NN
were_VBD
,_,
in_PIN
certain_JJ
circumstances_NN
,_,
entitled_VBN [PASTP]
to_PIN
a_DT
further_JJ
fee_NN
in_PIN
respect_NN
of_PIN
further_JJ
transactions_NOMZ
entered_VBD
into_PIN
by_PIN
CAT_NN
Limited_NN
in_PIN
the_DT
period_NN
up_IN
to_PIN
February_NN
2001_CD
._.
No_SYNE
such_JJ
further_JJ
transactions_NOMZ
or_CC
payments_NOMZ
have_VPRT [PEAS]
taken_VBN
place_NN
._.
J_NN
L_NN
Foght_NN
was_VBD [BEMA]
a_DT
managing_GER
director_NN
of_PIN
Prudential_NN
Vector_NN
at_PIN
the_DT
time_NN
the_DT
arrangement_NOMZ
was_VBD [PASS]
entered_VBN
into_PIN
and_CC
the_DT
payment_NOMZ
made_VBN
and_PHC
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
the_DT
Company_NN
._.
The_DT
Board_NN
of_PIN
Directors_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV] [THATD]
that_DEMP
this_DEMO
transaction_NOMZ
did_VBD
not_XX0
interfere_VB
with_PIN
Dr_NN
Foghts_NN
exercise_NN
of_PIN
independent_JJ
judgement_NOMZ
and_CC
accordingly_RB
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
he_TPP3
is_VPRT [BEMA]
an_DT
independent_JJ
Director_NN
under_IN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
that_THVC
it_PIT
is_VPRT [BEMA]
in_PIN
the_DT
best_JJ
interests_NN
of_PIN
the_DT
Company_NN
that_TOBJ
he_TPP3
continue_VPRT
to_TO
serve_VB
on_PIN
the_DT
Audit_NN
Committee_NN
._.
In_PIN
accordance_NN
with_PIN
FRS_NN
8_CD
,_,
Related_NN
Party_NN
Disclosures_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
disclose_VB [PUBV]
transactions_NOMZ
or_CC
balances_NN
between_PIN
group_NN
entities_NOMZ
which_WDT [WHSUB]
are_VPRT [SPAU] [PASS]
wholly_RB
eliminated_VBN
on_PIN
consolidation_NOMZ
._.
26_CD
Litigation_NOMZ
As_IN
previously_TIME
reported_VBN [PUBV]
,_,
CATs_NN
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
MorphoSys_NN
relating_VBG [WZPRES]
to_PIN
the_DT
European_JJ
Winter_NN
II_NN
and_PHC
McCafferty_NN
patents_NN
in_PIN
Munich_NN
is_VPRT [SPAU] [PASS]
currently_RB
stayed_VBN
pending_VBG
the_DT
outcome_NN
of_PIN
appeal_NN
proceedings_GER
at_PIN
the_DT
European_JJ
Patent_NN
Office_NN
._.
In_PIN
March_NN
2002_CD
the_DT
District_NN
Court_NN
in_PIN
Washington_NN
DC_NN
issued_VBD
a_DT
formal_JJ
ruling_NN
that_TOBJ
MorphoSys_NN
does_VPRT
not_XX0
infringe_VB
CATs_NN
US_FPP1
Griffiths_NN
patent_NN
._.
The_DT
decision_NN
was_VBD [PASS]
based_VBN
on_PIN
the_DT
method_NN
by_PIN
which_WDT [PIRE]
MorphoSys_NN
library_NN
is_VPRT [PASS]
derived_VBN
._.
CAT_NN
has_VPRT [PEAS]
appealed_VBN
this_DEMO
decision_NN
._.
The_DT
appeal_NN
will_PRMD
be_VB [PASS]
limited_VBN
to_PIN
the_DT
issue_NN
as_IN
to_PIN
whether_IN
MorphoSys_NN
infringes_VPRT
the_DT
Griffiths_NN
patent_NN
._.
A_DT
hearing_GER
date_NN
has_VPRT [PEAS]
not_XX0
yet_RB
been_VBN [PASS]
set_VBN
but_CC
it_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV]
that_THVC
the_DT
hearing_GER
will_PRMD
take_VB
place_NN
in_PIN
mid_JJ
2003_CD
._.
May_POMD
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
proposed_VBN [SUAV]
as_IN
the_DT
trial_NN
date_NN
for_PIN
the_DT
two_CD
legal_JJ
actions_NOMZ
in_PIN
the_DT
District_NN
Court_NN
in_PIN
Washington_NN
DC_NN
in_PIN
which_WDT [PIRE]
CAT_NN
claims_VPRT [PUBV]
that_THVC
MorphoSys_NN
infringes_VPRT
its_PIT
Winter_NN
II_NN
patent_NN
and_CC
two_CD
of_PIN
the_DT
Winter_NN
Lerner_NN
Huse_NN
patents_NN
._.
The_DT
preliminary_JJ
Markman_NN
Hearings_GER
on_PIN
these_DEMO
cases_NN
were_VBD [PASS]
postponed_VBN
._.
A_DT
new_JJ
date_NN
for_PIN
these_DEMO
hearings_GER
has_VPRT
yet_RB
to_TO
be_VB [BYPA]
set_VBN
by_PIN
the_DT
Court_NN
._.
A_DT
trial_NN
date_NN
of_PIN
17_CD
February_NN
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
proposed_VBN [SUAV]
for_PIN
the_DT
legal_JJ
action_NOMZ
brought_VBN [WZPAST]
by_PIN
MorphoSys_NN
in_PIN
respect_NN
of_PIN
CATs_NN
US_FPP1
McCafferty_NN
patent_NN
._.
The_DT
preliminary_JJ
Markman_NN
Hearing_GER
on_PIN
this_DEMO
case_NN
was_VBD [PASS]
postponed_VBN
._.
A_DT
new_JJ
date_NN
for_PIN
this_DEMO
hearing_GER
has_VPRT
yet_RB
to_TO
be_VB [BYPA]
set_VBN
by_PIN
the_DT
Court_NN
._.
As_IN
previously_TIME
reported_VBN [PUBV]
,_,
in_PIN
2000_CD
Crucell_NN
issued_VBD
writs_NN
against_PIN
the_DT
Medical_NN
Research_NN
Council_NN
MRC_NN
,_,
Scripps_NN
and_PHC
Stratagene_NN
in_PIN
a_DT
Dutch_JJ
national_JJ
court_NN
,_,
seeking_VBG [PRESP]
a_DT
declaration_NOMZ
that_TOBJ
the_DT
Winter_NN
II_NN
patent_NN
was_VBD [BEMA]
invalid_PRED
or_CC
that_THVC
Crucell_NN
did_VBD
not_XX0
infringe_VB
the_DT
claims_NN
of_PIN
the_DT
patent_NN
._.
A_DT
separate_JJ
writ_NN
against_PIN
MRC_NN
sought_VBD
a_DT
similar_JJ
declaration_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
McCafferty_NN
patent_NN
._.
Pursuant_JJ
to_PIN
its_PIT
agreements_NOMZ
with_PIN
the_DT
defendants_NN
,_,
CAT_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
defense_NN
of_PIN
these_DEMO
proceedings_GER
._.
The_DT
Court_NN
has_VPRT [PEAS]
declined_VBN
jurisdiction_NOMZ
for_PIN
Crucells_NN
non_NN
infringement_NOMZ
claims_NN
and_CC
assumed_VBD [PRIV]
jurisdiction_NOMZ
only_DWNT
on_PIN
the_DT
invalidity_NOMZ
claims_VPRT [PUBV] [THATD]
any_QUAN
decision_NN
will_PRMD [SPAU]
only_DWNT
cover_VB
Holland_NN
._.
The_DT
Courts_NN
ruling_VBG [SUAV] [WZPRES]
to_TO
decline_VB
jurisdiction_NOMZ
in_PIN
the_DT
Winter_NN
II_NN
case_NN
is_VPRT
currently_RB
under_IN
appeal_NN
by_PIN
Crucell_NN
._.
CAT_NN
intends_VPRT [SUAV]
to_TO
defend_VB
these_DEMO
proceedings_GER
vigorously_RB
and_CC
does_VPRT
not_XX0
believe_VB [PRIV]
there_EX
is_VPRT
merit_NN
in_PIN
these_DEMO
claims_NN
._.
Whatever_WDT
the_DT
outcome_NN
of_PIN
the_DT
above_PLACE
litigation_NOMZ
activity_NOMZ
,_,
CAT_NN
believes_VPRT [PRIV]
that_THVC
its_PIT
ability_NOMZ
to_TO
operate_VB
its_PIT
own_JJ
technology_NN
will_PRMD
not_XX0
be_VB
materially_RB
and_PHC
adversely_RB
affected_VBN
._.
As_IN
previously_TIME
reported_VBN [PUBV]
,_,
following_VBG
certain_JJ
share_NN
issues_NN
by_PIN
Cambridge_NN
Antibody_NN
Technology_NN
Limited_NN
,_,
Continental_NN
Venture_NN
Capital_NN
Limited_NN
CVC_NN
issued_VBD
proceedings_GER
in_PIN
the_DT
State_NN
of_PIN
New_NN
York_NN
claiming_VBG [PUBV] [WZPRES]
that_THVC
it_PIT
is_VPRT [PASS]
entitled_VBN
to_PIN
anti-dilution_JJ
shares_NN
equivalent_JJ
to_PIN
25,790_CD
ordinary_JJ
shares_NN
of_PIN
10p_JJ
each_QUAN
._.
If_COND
CVC_NN
succeeds_VPRT
then_RB
the_DT
Directors_NN
would_PRMD
be_VB [PASS]
obliged_VBN
to_TO
issue_VB
anti-dilution_JJ
shares_NN
to_PIN
all_QUAN
similarly_CONJ
situated_VBN
participants_NN
approximately_RB
763,000_CD
ordinary_JJ
shares_NN
of_PIN
10p_JJ
each_QUAN
._.
Both_DT
parties_NN
issued_VBD
cross_JJ
motions_NOMZ
for_PIN
summary_NN
judgement_NOMZ
which_WDT [WHSUB]
were_VBD [PASS]
denied_VBN [PUBV]
in_PIN
May_POMD
2000_CD
._.
There_EX
has_VPRT [PEAS]
been_VBN
no_SYNE
change_NN
in_PIN
the_DT
status_NN
of_PIN
proceedings_GER
during_PIN
the_DT
year_NN
and_CC
the_DT
Directors_NN
continue_VPRT
to_TO
believe_VB [PRIV]
,_,
on_PIN
the_DT
basis_NN
of_PIN
legal_JJ
advice_NN
they_TPP3
have_VPRT [PEAS]
received_VBN
,_,
that_THVC
the_DT
proceedings_GER
have_VPRT
no_SYNE
merit_NN
._.
61_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
Summary_NN
of_PIN
Significant_NN
Differences_NN
Between_PIN
UK_NN
GAAP_NN
Followed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
and_PHC
US_FPP1
GAAP_NN
The_NN
Groups_NN
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
,_,
which_WDT [SERE]
differs_VPRT
in_PIN
certain_JJ
significant_JJ
respects_NN
from_PIN
accounting_VBG
principles_NN
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
US_FPP1
GAAP_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
significant_JJ
adjustments_NOMZ
to_PIN
net_JJ
loss_NN
and_PHC
shareholders_NN
funds_NN
required_VBN [SUAV]
when_RB [WHCL]
reconciling_VBG
such_JJ
amounts_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
financial_JJ
statements_NOMZ
to_PIN
the_DT
corresponding_JJ
amounts_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
,_,
considering_VBG [PRIV] [PRESP]
the_DT
significant_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
._.
Reconciliation_NOMZ
of_PIN
net_JJ
loss_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
2002 2001 2000_CD
Notes_NN
000 000 000_CD
Net_JJ
loss_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
28,207_CD
11,771_CD
8,289_CD
Adjustments_NOMZ
for_PIN
:_:
Compensation_NOMZ
costs_NN
under_IN
variable_JJ
plan_NN
accounting_GER
for_PIN
stock_NN
options_NOMZ
a_DT
3,703_CD
7,804_CD
8,223_CD
Acquisition_NOMZ
of_PIN
Aptein_NN
Inc._NN
b_NN
16_CD
16_CD
16_CD
Revenue_NN
recognition_NOMZ
c_NN
422 422 111_CD
Accounting_GER
for_PIN
National_NN
Insurance_NN
on_PIN
share_NN
options_NOMZ
d_LS
248 194 523_CD
Reclassification_NOMZ
of_PIN
share_NN
issue_NN
expenses_NN
e_LS
202_CD
1,237_CD
Profit_NN
on_PIN
sale_NN
of_PIN
Denzyme_NN
ApS_NN
f_SYM
229_CD
Termination_NOMZ
of_PIN
DRC_NN
royalty_NN
agreement_NOMZ
g_NN
723_CD
Foreign_NN
exchange_NN
difference_NN
h_VPRT
491_CD
Net_JJ
loss_NN
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
31,291_CD
19,565_CD
17,131_CD
Loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
would_PRMD
compute_VB
loss_NN
per_PIN
share_NN
under_IN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
128_CD
,_,
basic_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
is_VPRT [BEMA]
computed_PRED
using_VBG
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
of_PIN
common_JJ
stock_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Diluted_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
for_PIN
CAT_NN
is_VPRT [BEMA]
the_DT
same_JJ
as_IN
basic_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
as_IN
the_DT
effects_NN
of_PIN
the_DT
Companys_NN
potential_JJ
ordinary_JJ
share_NN
equivalents_NN
are_VPRT [BEMA]
antidilutive_PRED
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
basis_NN
of_PIN
calculation_NOMZ
is_VPRT [BEMA]
the_DT
same_JJ
._.
However_CONJ
,_,
since_OSUB
different_JJ
net_JJ
losses_NN
are_VPRT [PASS]
produced_VBN
under_IN
US_FPP1
GAAP_NN
and_PHC
UK_NN
GAAP_NN
the_DT
net_JJ
loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
2002 2001 2000_CD
Basic_JJ
and_PHC
diluted_JJ
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
pence_NN
87.3_CD
55.4_CD
56.8_CD
Shares_NN
used_VBN [WZPAST]
in_PIN
computing_VBG
net_JJ
loss_NN
per_PIN
ordinary_JJ
share_NN
number_NN
35,828,446_CD
35,313,260_CD
30,179,818_CD
Antidilutive_JJ
securities_NOMZ
,_,
not_XX0
included_VBN
above_PLACE
number_NN
867,316_CD
1,077,800_CD
1,548,764_CD
Antidilutive_JJ
securities_NOMZ
represent_VPRT
stock_NN
options_NOMZ
outstanding_JJ
which_WDT
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
included_VBN
in_PIN
the_DT
calculation_NOMZ
of_PIN
loss_NN
per_PIN
ordinary_JJ
share_NN
as_IN
the_DT
impact_NN
of_PIN
including_VBG
such_JJ
shares_NN
in_PIN
the_DT
calculation_NOMZ
of_PIN
loss_NN
per_PIN
share_NN
would_PRMD
be_VB [BEMA]
antidilutive_PRED
._.
Reconciliation_NOMZ
of_PIN
shareholders_NN
funds_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
2002 2001 2000_CD
Notes_NN
000 000 000_CD
Shareholders_NN
funds_NN
as_IN
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
135,765_CD
156,050_CD
152,440_CD
Acquisition_NOMZ
of_PIN
Aptein_NN
Inc._NN
b_NN
127 143 159_CD
Revenue_NN
recognition_NOMZ
c_NN
2,375_CD
2,797_CD
1,768_CD
Accounting_GER
for_PIN
National_NN
Insurance_NN
on_PIN
stock_NN
options_NOMZ
d_LS
81 329 523_CD
Shareholders_NN
funds_NN
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
133,598_CD
153,725_CD
151,354_CD
62_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
Reconciliation_NOMZ
of_PIN
movement_NOMZ
in_PIN
shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
Share_NN
Total_NN
shareholders_NN
Number_NN
of_PIN
shares_NN
Share_NN
capital_NN
premium_NN
account_NN
Other_JJ
reserve_NN
Accumulated_VBN
loss_NN
equity_NOMZ
000 000 000 000_CD
000_CD
000_CD
Balance_NN
,_,
30_CD
September_NN
2000_CD
34,770,438_CD
3,477_CD
187,274_CD
13,492_CD
52,889_CD
151,354_CD
Shares_NN
issued_VBN
685,427_CD
69_CD
14,062_CD
14,131_CD
Compensation_NOMZ
costs_NN
for_PIN
stock_NN
options_NOMZ
7,804_CD
7,804_CD
Foreign_JJ
exchange_NN
translation_NOMZ
11_CD
Net_JJ
loss_NN
for_PIN
the_DT
year_NN
under_IN
US_FPP1
GAAP_NN
19,565_CD
19,565_CD
Total_JJ
comprehensive_JJ
income_NN
19,564_CD
Balance_NN
,_,
30_CD
September_NN
2001_CD
35,455,865_CD
3,546_CD
209,140_CD
13,492_CD
72,453_CD
153,725_CD
Shares_NN
issued_VBN
758,484_CD
75_CD
6,794_CD
5_CD
6,874_CD
Compensation_NOMZ
costs_NN
for_PIN
stock_NN
options_NOMZ
3,703_CD
3,703_CD
Foreign_JJ
exchange_NN
translation_NOMZ
587_CD
587_CD
Net_JJ
loss_NN
for_PIN
the_DT
year_NN
under_IN
US_FPP1
GAAP_NN
31,291_CD
31,291_CD
Total_JJ
comprehensive_JJ
income_NN
30,704_CD
Balance_NN
,_,
30_CD
September_NN
2002_CD
36,214,349_CD
3,621_CD
219,637_CD
13,497_CD
103,157_CD
133,598_CD
Total_JJ
accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
foreign_JJ
currency_NN
translations_NOMZ
at_PIN
30_CD
September_NN
2001_CD
was_VBD [BEMA]
1,000_CD
and_CC
at_PIN
30_CD
September_NN
2002_CD
was_VBD [BEMA]
588,000_CD
._.
a_DT
Compensation_NOMZ
costs_NN
under_IN
variable_JJ
plan_NN
accounting_GER
for_PIN
stock_NN
options_NOMZ
._.
CAT_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
stock_NN
options_NOMZ
to_PIN
employees_NN
that_TSUB
will_PRMD
vest_NN
upon_PIN
the_DT
attainment_NOMZ
of_PIN
certain_JJ
targets_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
there_EX
is_VPRT
no_SYNE
accounting_GER
for_PIN
the_DT
cost_NN
of_PIN
these_DEMO
grants_NN
after_IN
the_DT
initial_JJ
grant_NN
date_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
Accounting_GER
Principles_NN
Board_NN
APB_NN
Opinion_NN
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
,_,
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
follow_VB
variable_JJ
plan_NN
accounting_GER
for_PIN
these_DEMO
grants_NN
._.
The_DT
nature_NN
of_PIN
conditions_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
stock_NN
options_NOMZ
awards_NN
mean_VPRT [PRIV]
that_THVC
management_NOMZ
can_POMD
not_XX0
make_VB
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
number_NN
of_PIN
shares_NN
that_TSUB
will_PRMD
be_VB [SPAU] [PASS]
eventually_TIME
issued_VBN
because_CAUS
the_DT
Company_NN
can_POMD
not_XX0
control_VB
the_DT
achievements_NOMZ
of_PIN
the_DT
conditions_NOMZ
._.
As_CONJ
a_NULL
consequence_NULL
,_,
the_DT
compensation_NOMZ
expense_NN
for_PIN
the_DT
stock_NN
awards_NN
is_VPRT [PASS]
recorded_VBN
when_RB
and_CC
only_DWNT
when_RB
the_DT
options_NOMZ
vest_NN
when_RB
the_DT
target_NN
is_VPRT [PASS]
achieved_VBN
,_,
based_VBN [PASTP]
on_PIN
the_DT
difference_NN
between_PIN
the_DT
exercise_NN
price_NN
and_PHC
market_NN
value_NN
at_PIN
that_DEMO
date_NN
._.
The_DT
targets_NN
were_VBD [SPAU] [PASS]
first_RB
achieved_VBN
in_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2000_CD
._.
There_EX
is_VPRT
no_SYNE
tax_NN
effect_NN
related_VBN [WZPAST]
to_PIN
the_DT
adjustments_NOMZ
in_PIN
respect_NN
of_PIN
stock_NN
options_NOMZ
._.
b_NN
Accounting_GER
for_PIN
the_DT
acquisition_NOMZ
of_PIN
Aptein_NN
Inc._NN
._.
The_DT
Company_NN
acquired_VBD
Aptein_NN
Inc._NN
._.
Aptein_NN
in_PIN
July_NN
1998_CD
for_PIN
consideration_NOMZ
payable_JJ
partly_DWNT
on_PIN
completion_NOMZ
,_,
the_DT
remainder_NN
being_VBG [WZPRES] [PASS]
deferred_VBN
,_,
payable_JJ
subject_NN
to_PIN
the_DT
achievement_NOMZ
of_PIN
certain_JJ
conditions_NOMZ
._.
Aptein_NN
was_VBD [PASS]
acquired_VBN
for_PIN
its_PIT
patent_NN
portfolio_NN
,_,
which_WDT [SERE]
comprised_VBD
its_PIT
only_DWNT
material_NN
asset_NN
._.
The_DT
value_NN
of_PIN
purchase_NN
consideration_NOMZ
therefore_CONJ
had_VBD
a_DT
corresponding_JJ
impact_NN
on_PIN
the_DT
fair_JJ
value_NN
ascribed_VBD
to_PIN
the_DT
patents_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
an_DT
intangible_JJ
asset_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
in_PIN
accordance_NN
with_PIN
FRS_NN
7_CD
Fair_NN
Values_NN
in_PIN
Acquisition_NOMZ
Accounting_GER
,_,
the_DT
fair_JJ
value_NN
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
was_VBD [PASS]
recognized_VBN [PRIV]
immediately_TIME
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
which_WDT [WHSUB]
was_VBD [BEMA]
payable_PRED
by_PIN
the_DT
issue_NN
of_PIN
shares_NN
in_PIN
the_DT
Company_NN
was_VBD [PASS]
reported_VBN [PUBV]
as_IN
part_NN
of_PIN
shareholders_NN
funds_NN
as_IN
shares_NN
to_TO
be_VB [PASS]
issued_VBN
._.
The_DT
difference_NN
between_PIN
the_DT
initial_JJ
investment_NOMZ
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
and_CC
the_DT
actual_JJ
amount_NN
was_VBD [PASS]
recorded_VBN
as_IN
an_DT
adjustment_NOMZ
to_PIN
the_DT
purchase_NN
price_NN
in_PIN
June_NN
1999_CD
,_,
when_RB
paid_VBN
._.
At_PIN
this_DEMO
time_NN
a_DT
corresponding_JJ
adjustment_NOMZ
to_PIN
the_DT
value_NN
of_PIN
the_DT
intangible_JJ
asset_NN
was_VBD [SPAU] [PASS]
also_RB
recognized_VBN [PRIV]
._.
Under_IN
US_FPP1
GAAP_NN
,_,
APB_NN
Opinion_NN
16_CD
,_,
Accounting_GER
for_PIN
Business_NOMZ
Combinations_NOMZ
,_,
contingent_JJ
consideration_NOMZ
is_VPRT [PASS]
not_XX0
recorded_VBN
until_IN
such_JJ
time_NN
as_IN
the_DT
contingency_NN
is_VPRT [PASS]
resolved_VBN [SUAV]
._.
Accordingly_RB
,_,
prior_RB
to_PIN
the_DT
actual_JJ
payment_NOMZ
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
the_DT
recorded_VBN
value_NN
of_PIN
the_DT
intangible_JJ
asset_NN
under_IN
US_FPP1
GAAP_NN
was_VBD [BEMA]
lower_PRED
than_PIN
under_IN
UK_NN
GAAP_NN
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
lower_JJ
amortisation_NOMZ
charge_NN
._.
On_PIN
payment_NOMZ
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
,_,
the_DT
amortisation_NOMZ
charge_NN
under_IN
US_FPP1
GAAP_NN
increased_VBD
above_PLACE
UK_NN
GAAP_NN
as_CONJ
a_NULL
consequence_NULL
of_PIN
the_DT
higher_JJ
unamortised_JJ
cost_NN
._.
63_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
c_NN
Revenue_NN
recognition_NOMZ
._.
The_DT
nature_NN
of_PIN
the_DT
Groups_NN
principal_JJ
revenue_NN
streams_NN
and_CC
the_DT
Groups_NN
accounting_VBG [WZPRES]
policy_NN
for_PIN
revenue_NN
recognition_NOMZ
under_IN
UK_NN
GAAP_NN
are_VPRT
as_IN
detailed_VBN
in_PIN
note_NN
1_CD
._.
For_PIN
US_FPP1
GAAP_NN
purposes_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
adopted_VBN
,_,
for_PIN
all_QUAN
periods_NN
,_,
Staff_NN
Accounting_GER
Bulletin_NN
101_CD
SAB101_CD
,_,
Revenue_NN
Recognition_NOMZ
in_PIN
Financial_NN
Statements_NOMZ
,_,
which_WDT [SERE]
was_VBD [BYPA]
issued_VBN
by_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
in_PIN
December_NN
1999_CD
._.
The_DT
treatment_NOMZ
of_PIN
revenues_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
that_DEMO
under_IN
UK_NN
GAAP_NN
except_PIN
as_IN
follows_VPRT
:_:
Under_IN
US_FPP1
GAAP_NN
,_,
where_RB
licensing_GER
arrangements_NOMZ
are_VPRT [BYPA]
accompanied_VBN
by_PIN
an_DT
equity_NOMZ
subscription_NOMZ
agreement_NOMZ
,_,
the_DT
series_NN
of_PIN
transactions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
multiple_JJ
elements_NOMZ
arrangement_NOMZ
._.
Accordingly_RB
the_DT
aggregate_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
the_DT
two_CD
elements_NOMZ
of_PIN
the_DT
arrangement_NOMZ
as_IN
follows_VPRT
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
equity_NOMZ
subscription_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
being_VBG [BEMA]
the_DT
aggregate_JJ
number_NN
of_PIN
shares_NN
issued_VBN [WZPAST]
at_PIN
the_DT
average_NN
of_PIN
the_DT
opening_GER
and_PHC
closing_GER
share_NN
prices_NN
on_PIN
the_DT
date_NN
of_PIN
issue_NN
._.
Any_QUAN
deficit_NN
or_CC
premium_NN
arising_VBG [WZPRES]
from_PIN
the_DT
aggregate_JJ
value_NN
of_PIN
the_DT
share_NN
subscription_NOMZ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
is_VPRT [PASS]
recorded_VBN
as_IN
an_DT
adjustment_NOMZ
to_PIN
licence_NN
revenues_NN
._.
No_SYNE
such_JJ
reallocation_NOMZ
is_VPRT [PASS]
made_VBN
under_IN
UK_NN
GAAP_NN
._.
During_PIN
the_DT
years_NN
ended_VBN
30_CD
September_NN
2002_CD
and_CC
2001_CD
licence_NN
revenues_NN
under_IN
US_FPP1
GAAP_NN
were_VBD [BEMA]
therefore_CONJ
422,000_CD
higher_JJ
._.
For_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2000_CD
licence_NN
revenues_NN
under_IN
US_FPP1
GAAP_NN
were_VBD [BEMA]
111,000_CD
higher_JJ
._.
d_LS
Accounting_GER
for_PIN
National_NN
Insurance_NN
on_PIN
share_NN
options_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
the_DT
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
a_DT
potential_JJ
liability_NOMZ
to_PIN
National_NN
Insurance_NN
on_PIN
employee_NN
share_NN
options_NOMZ
._.
The_DT
provision_NN
is_VPRT
being_VBG [PASS]
made_VBN
systematically_RB
by_PIN
reference_NN
to_PIN
the_DT
market_NN
value_NN
of_PIN
shares_NN
at_PIN
the_DT
balance_NN
sheet_NN
dates_NN
over_IN
the_DT
period_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
to_PIN
the_DT
end_NN
of_PIN
the_DT
relevant_JJ
performance_NN
period_NN
and_CC
from_PIN
that_DEMO
date_NN
to_PIN
the_DT
date_NN
of_PIN
actual_JJ
exercise_NN
the_DT
provision_NN
will_PRMD
be_VB [BYPA]
adjusted_VBN
by_PIN
reference_NN
to_PIN
changes_NN
in_PIN
market_NN
value_NN
._.
The_DT
provision_NN
at_PIN
30_CD
September_NN
2002_CD
was_VBD [BEMA]
81,000_CD
and_CC
the_DT
net_JJ
credit_NN
for_PIN
the_DT
year_NN
then_RB
ended_VBD
amounted_VBD
to_PIN
248,000_CD
._.
Under_IN
US_FPP1
GAAP_NN
,_,
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
Issue_NN
00-16_CD
Recognition_NOMZ
and_PHC
Measurement_NOMZ
of_PIN
Employer_NN
Payroll_NN
Taxes_NN
on_PIN
Employee_NN
Stock-Based_NN
Compensation_NOMZ
,_,
no_SYNE
liability_NOMZ
to_PIN
National_NN
Insurance_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
until_IN
such_JJ
time_NN
as_IN
the_DT
share_NN
option_NOMZ
is_VPRT [PASS]
exercised_VBN
since_OSUB
this_DEMP
is_VPRT
when_RB
the_DT
liability_NOMZ
crystallises_NN
._.
Under_IN
the_DT
agreement_NOMZ
with_PIN
DRC_NN
the_DT
Group_NN
received_VBD
an_DT
amount_NN
of_PIN
1.5_CD
million_CD
in_PIN
1994_CD
in_PIN
exchange_NN
for_PIN
rights_NN
to_PIN
a_DT
percentage_NN
of_PIN
the_DT
cash_NN
receivable_NN
in_PIN
respect_NN
of_PIN
certain_JJ
revenues_NN
and_CC
certain_JJ
equity_NOMZ
issues_NN
where_RB
these_DEMO
equity_NOMZ
issues_NN
form_VPRT
part_NN
of_PIN
a_DT
commercial_JJ
collaboration_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
amounts_VPRT
paid_VBN
to_PIN
DRC_NN
as_CONJ
a_NULL
result_NULL
of_PIN
an_DT
equity_NOMZ
subscription_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
share_NN
issue_NN
expense_NN
since_OSUB
they_TPP3
are_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [SPAU] [PASS]
directly_RB
related_VBN
to_PIN
the_DT
share_NN
issue_NN
._.
Under_IN
US_FPP1
GAAP_NN
these_DEMO
amounts_NN
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
share_NN
issue_NN
cost_NN
since_OSUB
DRC_NN
are_VPRT
not_XX0
providing_VBG
any_QUAN
services_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
equity_NOMZ
issue_NN
._.
Accordingly_RB
,_,
such_JJ
amounts_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
year_NN
under_IN
US_FPP1
GAAP_NN
._.
f_LS
Profit_NN
on_PIN
sale_NN
of_PIN
Denzyme_NN
ApS_NN
._.
Goodwill_NN
of_PIN
229,000_CD
arose_VBD
on_PIN
the_DT
purchase_NN
of_PIN
Denzume_NN
ApS_NN
in_PIN
June_NN
1996_CD
._.
In_PIN
accordance_NN
with_PIN
the_DT
UK_NN
accounting_GER
standard_NN
then_RB
in_PIN
force_NN
Statement_NOMZ
of_PIN
Standard_NN
Accounting_GER
Practice_NN
22_CD
this_DEMO
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
goodwill_NN
was_VBD [PASS]
expensed_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
Company_NN
sold_VBD
Denzyme_NN
ApS_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
,_,
in_PIN
November_NN
2001_CD
._.
Under_IN
UK_NN
GAAP_NN
the_DT
calculated_JJ
profit_NN
on_PIN
disposal_NN
takes_VPRT
account_NN
of_PIN
the_DT
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
resulting_VBG [WZPRES]
in_PIN
a_DT
profit_NN
on_PIN
disposal_NN
of_PIN
2,000_CD
._.
Under_IN
US_FPP1
GAAP_NN
there_EX
is_VPRT
no_SYNE
requirement_NOMZ
to_TO
write_VB [PUBV]
back_RP
the_DT
goodwill_NN
as_IN
it_PIT
has_VPRT [SPAU] [PEAS]
already_RB
been_VBN [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Therefore_CONJ
under_IN
US_FPP1
GAAP_NN
the_DT
profit_NN
on_PIN
disposal_NN
of_PIN
Denzyme_NN
ApS_NN
is_VPRT [BEMA]
231,000_CD
._.
g_NN
Termination_NOMZ
of_PIN
DRC_NN
royalty_NN
agreement_NOMZ
._.
Under_IN
an_DT
agreement_NOMZ
with_PIN
DRC_NN
the_DT
Group_NN
received_VBD
a_DT
payment_NOMZ
of_PIN
1.5_CD
million_CD
in_PIN
1994_CD
in_PIN
return_NN
for_PIN
rights_NN
to_PIN
a_DT
percentage_NN
of_PIN
revenues_NN
and_CC
certain_JJ
other_JJ
payments_NOMZ
received_VBN [WZPAST]
by_PIN
the_DT
Group_NN
over_IN
a_DT
period_NN
terminating_VBG [WZPRES]
in_PIN
2009_CD
._.
On_PIN
2_CD
May_POMD
2002_CD
the_DT
Group_NN
bought_VBD
out_PIN
this_DEMO
obligation_NOMZ
to_PIN
DRC_NN
for_PIN
6.1_CD
million_CD
C$_$
14_CD
million_CD
with_PIN
the_DT
issue_NN
of_PIN
463,818_CD
CAT_NN
shares_NN
to_PIN
DRC_NN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
share_NN
price_NN
applied_VBD
to_PIN
this_DEMO
transaction_NOMZ
defined_VBN [WZPAST]
in_PIN
the_DT
contract_NN
,_,
was_VBD [BEMA]
the_DT
volume_NN
weighted_VBN
average_JJ
closing_GER
CAT_NN
share_NN
price_NN
over_IN
the_DT
ten_CD
days_NN
prior_RB
to_PIN
30_CD
April_NN
2002_CD
,_,
being_VBG [PRESP] [BEMA]
the_DT
date_NN
that_TOBJ
the_DT
Group_NN
notified_VBN
DRC_NN
that_TOBJ
they_TPP3
intended_VBD [SUAV]
to_TO
terminate_VB
the_DT
royalty_NN
agreement_NOMZ
._.
This_DEMP
resulted_VBD
in_PIN
a_DT
credit_NN
to_PIN
the_DT
share_NN
premium_NN
account_NN
of_PIN
6,102,000_CD
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
share_NN
price_NN
applied_VBD
was_VBD [BEMA]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
closing_GER
CAT_NN
share_NN
price_NN
on_PIN
the_DT
30_CD
April_NN
2002_CD
,_,
resulting_VBG [PRESP]
in_PIN
a_DT
credit_NN
to_PIN
the_DT
share_NN
premium_NN
account_NN
of_PIN
5,379,000_CD
._.
h_NN
Foreign_NN
currency_NN
translation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
results_NN
of_PIN
overseas_PLACE
subsidiaries_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
closing_GER
exchange_NN
rate_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
average_JJ
exchange_NN
rate_NN
for_PIN
the_DT
year_NN
is_VPRT [PASS]
used_VBN
._.
64_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
i_FPP1
Taxation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
on_PIN
timing_NN
differences_NN
which_WDT [WHSUB]
result_VPRT
in_PIN
an_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
to_TO
pay_VB
more_EMPH
tax_NN
,_,
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
,_,
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
Net_JJ
deferred_VBN
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
deferred_VBN
tax_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
in_PIN
respect_NN
of_PIN
temporary_JJ
differences_NN
between_PIN
the_DT
reported_VBN [PUBV]
carrying_VBG
amount_NN
of_PIN
an_DT
asset_NN
or_CC
liability_NOMZ
and_CC
its_PIT
corresponding_JJ
tax_NN
basis_NN
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [SPAU] [PASS]
also_RB
recognized_VBN [PRIV]
in_PIN
full_JJ
subject_NN
to_PIN
a_DT
valuation_NOMZ
allowance_NN
to_TO
reduce_VB
the_DT
amount_NN
of_PIN
such_JJ
assets_NN
to_PIN
that_DEMP
which_WDT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
to_TO
be_VB [PASS]
realized_VBN [PRIV]
._.
As_IN
at_PIN
30_CD
September_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
,_,
CAT_NN
has_VPRT
approximately_RB
79_CD
million_CD
,_,
60_CD
million_CD
and_CC
36_CD
million_CD
respectively_RB
of_PIN
cumulative_JJ
tax_NN
losses_NN
._.
These_DEMO
losses_NN
represent_VPRT
a_DT
deferred_JJ
tax_NN
asset_NN
for_PIN
accounting_GER
purposes_NN
._.
In_PIN
accordance_NN
with_PIN
both_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
,_,
no_SYNE
asset_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
these_DEMO
tax_NN
losses_NN
due_JJ
to_PIN
the_DT
uncertainty_NN
as_IN
to_PIN
whether_IN
these_DEMO
losses_NN
can_POMD
be_VB [PASS]
offset_VBN
against_PIN
future_JJ
profits_NN
._.
No_SYNE
tax_NN
effect_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
reconciliation_NOMZ
of_PIN
net_JJ
loss_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
in_PIN
respect_NN
of_PIN
the_DT
differences_NN
arising_VBG [WZPRES]
in_PIN
respect_NN
of_PIN
those_DEMO
items_NN
,_,
as_IN
the_DT
timing_NN
differences_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
offset_VBN
in_PIN
full_JJ
by_PIN
the_DT
unrecognised_JJ
tax_NN
losses_NN
carried_VBD
forward_RB
._.
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_VPRT
The_DT
consolidated_JJ
statements_NOMZ
of_PIN
cash_NN
flows_NN
prepared_VBN
under_IN
UK_NN
GAAP_NN
presents_VPRT
substantially_RB
the_DT
same_JJ
information_NOMZ
as_IN
that_DEMP
required_VBN [SUAV]
under_IN
US_FPP1
GAAP_NN
by_PIN
SFAS_NN
95_CD
Statement_NOMZ
of_PIN
Cash_NN
Flows_NN
._.
These_DEMO
standards_NN
differ_VPRT
however_CONJ
with_PIN
regard_NN
to_PIN
classification_NOMZ
of_PIN
items_NN
within_PIN
the_DT
statements_NOMZ
and_CC
the_DT
definition_NOMZ
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
cash_NN
comprises_VPRT
only_DWNT
cash_NN
in_PIN
hand_NN
and_PHC
deposits_NN
repayable_JJ
on_PIN
demand_NN
._.
Deposits_NN
are_VPRT [BEMA]
repayable_PRED
on_PIN
demand_NN
if_COND
they_TPP3
can_POMD
be_VB [PASS]
withdrawn_VBN
at_PIN
any_QUAN
time_NN
without_PIN
notice_NN
and_CC
without_PIN
penalty_NN
or_CC
if_COND
a_DT
maturity_NOMZ
or_CC
period_NN
of_PIN
notice_NN
of_PIN
not_XX0
more_EMPH
than_PIN
24_CD
hours_NN
or_CC
one_CD
working_VBG
day_NN
has_VPRT [PEAS]
been_VBN [PASS]
agreed_VBN [SUAV] [PUBV]
._.
Under_IN
US_FPP1
GAAP_NN
,_,
cash_NN
equivalents_NN
are_VPRT [BEMA]
short_JJ
term_NN
highly_AMP
liquid_JJ
investments_NOMZ
,_,
generally_RB
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
,_,
that_DEMP
are_VPRT [BEMA]
readily_RB
convertible_PRED
to_PIN
known_JJ
amounts_NN
of_PIN
cash_NN
and_CC
present_JJ
insignificant_JJ
risk_NN
of_PIN
changes_NN
in_PIN
value_NN
because_CAUS
of_PIN
changes_NN
in_PIN
interest_NN
rates_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
cash_NN
flows_NN
are_VPRT [PASS]
presented_VBN
separately_RB
for_PIN
operating_VBG
activities_NOMZ
,_,
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
,_,
taxation_NOMZ
,_,
capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
,_,
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
activities_NOMZ
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
only_DWNT
three_CD
categories_NN
of_PIN
cash_NN
flow_NN
activity_NOMZ
to_TO
be_VB [PASS]
reported_VBN [PUBV]
:_:
operating_GER
,_,
investing_VBG
and_PHC
financing_VBG
._.
Cash_NN
flows_VPRT
from_PIN
taxation_NOMZ
and_PHC
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
under_IN
UK_NN
GAAP_NN
would_PRMD
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
dividends_NN
paid_VBN
,_,
be_VB [PASS]
shown_VBN [PRIV]
under_IN
operating_VBG
activities_NOMZ
under_IN
US_FPP1
GAAP_NN
._.
The_DT
payment_NOMZ
of_PIN
dividends_NN
and_CC
the_DT
payment_NOMZ
to_TO
acquire_VB
own_JJ
shares_NN
treasury_NN
stock_NN
would_PRMD
be_VB [PASS]
included_VBN
as_IN
a_DT
financing_GER
activity_NOMZ
under_IN
US_FPP1
GAAP_NN
._.
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
under_IN
UK_NN
GAAP_NN
would_PRMD
be_VB [PASS]
included_VBN
as_IN
cash_NN
and_PHC
cash_NN
equivalents_NN
._.
Under_IN
US_FPP1
GAAP_NN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
would_PRMD
be_VB [PASS]
included_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
amounts_NN
involved_VBN
have_VPRT
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
and_CC
are_VPRT [BEMA]
convertible_PRED
into_PIN
known_JJ
amounts_NN
of_PIN
cash_NN
._.
Summary_JJ
statements_NOMZ
of_PIN
cash_NN
flow_NN
presented_VBN
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
given_VBN
below_PLACE
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
provided_VBN
by_PIN
operating_VBG
activities_NOMZ
18,330_CD
10,828_CD
636_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
5,106_CD
21,735_CD
32,725_CD
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
financing_VBG
activities_NOMZ
1,448_CD
15,380_CD
132,293_CD
Effects_NN
of_PIN
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
32_CD
2_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
22,020_CD
17,183_CD
100,206_CD
Beginning_GER
cash_NN
and_PHC
cash_NN
equivalents_NN
90,599_CD
107,782_CD
7,576_CD
Ending_GER
cash_NN
and_PHC
cash_NN
equivalents_NN
68,579_CD
90,599_CD
107,782_CD
65_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
A_DT
reconciliation_NOMZ
between_PIN
the_DT
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
is_VPRT [PASS]
presented_VBN
below_PLACE
for_PIN
the_DT
years_NN
ended_VBN
30_CD
September_NN
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Operating_GER
activities_NOMZ
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
operating_VBG
activities_NOMZ
under_IN
UK_NN
GAAP_NN
26,808_CD
19,150_CD
3,609_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
7,558_CD
8,322_CD
4,245_CD
Taxation_NOMZ
920_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
operating_VBG
activities_NOMZ
under_IN
US_FPP1
GAAP_NN
18,330_CD
10,828_CD
636_CD
Investing_VBG
activities_NOMZ
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
under_IN
UK_NN
GAAP_NN
9,961_CD
3,481_CD
974_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
under_IN
UK_NN
GAAP_NN
29,534_CD
274_CD
133,729_CD
Cash_NN
equivalents_NN
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
24,679_CD
18,528_CD
101,978_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
5,106_CD
21,735_CD
32,725_CD
Movement_NOMZ
in_PIN
cash_NN
Increase_VPRT
decrease_NN
in_PIN
cash_NN
under_IN
UK_NN
GAAP_NN
2,691_CD
1,345_CD
1,774_CD
Cash_NN
equivalents_NN
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
24,679_CD
18,528_CD
101,978_CD
Effects_NN
of_PIN
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
32_CD
2_CD
22,020_CD
17,183_CD
100,206_CD
Accounting_GER
for_PIN
share-based_JJ
compensation_NOMZ
As_IN
permitted_VBN
under_IN
SFAS_NN
123_CD
,_,
Accounting_GER
for_PIN
Stock-Based_NN
Compensation_NOMZ
,_,
in_PIN
accounting_GER
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
its_PIT
share_NN
option_NOMZ
schemes_NN
the_DT
Group_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
disclosure_NN
provisions_NN
of_PIN
SFAS_NN
123_CD
,_,
but_CC
opted_VBD
to_TO
remain_VB
under_IN
the_DT
expense_NN
recognition_NOMZ
provisions_NN
of_PIN
APB_NN
Opinion_NN
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
._.
Accordingly_RB
,_,
for_PIN
the_DT
years_NN
ended_VBN
30_CD
September_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
,_,
compensation_NOMZ
expenses_NN
of_PIN
3,703,000_CD
,_,
7,804,000_CD
and_CC
8,223,000_CD
were_VBD [PASS]
recognized_VBN [PRIV]
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
these_DEMO
schemes_NN
._.
Had_VBD
compensation_NOMZ
expense_NN
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
these_DEMO
schemes_NN
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
fair_JJ
value_NN
at_PIN
the_DT
grant_NN
dates_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
123_CD
,_,
the_DT
Companys_NN
charge_NN
to_PIN
income_NN
for_PIN
the_DT
years_NN
ending_VBG [WZPRES]
30_CD
September_NN
2002_CD
,_,
2001_CD
and_CC
2000_CD
would_PRMD
have_VB [PEAS]
been_VBN [BEMA]
1,523,000_CD
,_,
1,064,000_CD
and_CC
814,000_CD
respectively_RB
._.
In_PIN
calculating_VBG [PRIV]
these_DEMO
amounts_NN
,_,
the_DT
fair_JJ
value_NN
of_PIN
the_DT
options_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
amortised_VBN
over_IN
their_TPP3
respective_JJ
vesting_GER
periods_NN
._.
Net_JJ
loss_NN
and_PHC
loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
would_PRMD [SPAU]
therefore_CONJ
have_VB [PEAS]
been_VBN [PASS]
reduced_VBN
to_PIN
the_DT
pro_PIN
forma_FW
amounts_VPRT
shown_VBN [PRIV]
below_PLACE
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Pro_PIN
forma_FW
net_JJ
loss_NN
29,111_CD
12,825_CD
9,722_CD
Pro_PIN
forma_FW
net_JJ
loss_NN
per_PIN
share_NN
basic_JJ
and_CC
fully_AMP
diluted_VBN
81.3_CD
p_NN
36.3_CD
p_NN
32.2_CD
p_VPRT
Reported_VBN [PUBV]
net_JJ
loss_NN
31,291_CD
19,565_CD
17,131_CD
Reported_VBN [PUBV]
net_JJ
loss_NN
per_PIN
share_NN
basic_JJ
and_CC
fully_AMP
diluted_VBN
87.3_CD
p_NN
55.4_CD
p_VPRT
56.8_CD
p_JJ
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
was_VBD [PASS]
estimated_VBN [PRIV]
using_VBG
the_DT
Black-Scholes_NN
stock_NN
option_NOMZ
pricing_GER
model_NN
using_VBG [WZPRES]
the_DT
following_VBG
weighted_JJ
average_JJ
assumptions_NOMZ
:_:
Annual_JJ
standard_JJ
Risk-free_JJ
Expected_VBN [PRIV]
life_NN
Year_NN
ending_VBG [WZPRES]
Dividend_NN
yield_NN
deviation_NOMZ
volatility_NOMZ
interest_NN
rate_NN
Years_NN
30_CD
September_NN
2002_CD
0_CD
%_NN
65_CD
%_NN
4.9_CD
%_NN
5.5_CD
30_CD
September_NN
2001_CD
0_CD
%_NN
75_CD
%_NN
5.3_CD
%_NN
5.5_CD
30_CD
September_NN
2000_CD
0_CD
%_NN
75_CD
%_NN
6.1_CD
%_NN
5.5_CD
66_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
For_PIN
the_DT
purposes_NN
of_PIN
the_DT
following_VBG
tabulations_NOMZ
,_,
Weighted_NN
Average_NN
Exercise_NN
Price_NN
is_VPRT [BEMA]
abbreviated_PRED
to_PIN
WAEP_NN
,_,
Weighted_NN
Average_NN
Fair_NN
Value_NN
to_PIN
WAFV_NN
and_PHC
Weighted_NN
Average_NN
Remaining_VBG [WZPRES]
Contractual_NN
Life_NN
to_PIN
WARCL_NN
._.
Exercisable_JJ
as_IN
at_PIN
Outstanding_JJ
as_IN
at_PIN
30_CD
September_NN
2002_CD
30_CD
September_NN
2002_CD
Range_NN
of_PIN
exercise_NN
prices_NN
WAEP_NN
WARCL_NN
WAEP_NN
Number_NN
Years_NN
Number_NN
0_CD
0.99_CD
1_CD
2.99_CD
699,450_CD
2.66_CD
4.32_CD
224,718_CD
2.20_CD
3_CD
4.99_CD
189,179_CD
3.06_CD
3.78_CD
189,179_CD
3.06_CD
5_CD
9.99_CD
249,760_CD
5.02_CD
3.79_CD
249,760_CD
5.02_CD
10_CD
19.99_CD
269,883_CD
14.88_CD
9.34_CD
20_CD
31_CD
93,535_CD
29.46_CD
6.33_CD
Total_JJ
1,501,807_CD
6.97_CD
5.19_CD
663,657_CD
3.51_CD
Exercisable_JJ
as_IN
at_PIN
Outstanding_JJ
as_IN
at_PIN
30_CD
September_NN
2001_CD
30_CD
September_NN
2001_CD
Range_NN
of_PIN
exercise_NN
prices_NN
WAEP_NN
WARCL_NN
WAEP_NN
Number_NN
Years_NN
Number_NN
0_CD
0.99_CD
1_CD
2.99_CD
766,149_CD
2.63_CD
5.26_CD
45,350_CD
1.28_CD
3_CD
4.99_CD
374,924_CD
3.03_CD
4.21_CD
357,929_CD
3.03_CD
5_CD
10_CD
277,760_CD
5.02_CD
4.84_CD
260,260_CD
5.02_CD
21_CD
31_CD
99,145_CD
29.49_CD
7.29_CD
Total_JJ
1,517,978_CD
4.92_CD
3.95_CD
663,539_CD
3.69_CD
67_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
Exercisable_JJ
as_IN
at_PIN
Outstanding_JJ
as_IN
at_PIN
30_CD
September_NN
2000_CD
30_CD
September_NN
2000_CD
Range_NN
of_PIN
exercise_NN
prices_NN
WAEP_NN
WARCL_NN
WAEP_NN
Number_NN
Years_NN
Number_NN
0_CD
0.99_CD
1_CD
2.99_CD
870,470_CD
2.49_CD
6.10_CD
137,794_CD
1.31_CD
3_CD
4.99_CD
434,253_CD
3.03_CD
5.31_CD
417,258_CD
3.03_CD
5_CD
10_CD
488,660_CD
5.01_CD
5.88_CD
148,860_CD
5.03_CD
21_CD
31_CD
3,264_CD
23.03_CD
9.65_CD
Total_JJ
1,796,647_CD
3.34_CD
5.76_CD
703,912_CD
3.12_CD
Deferred_JJ
tax_NN
A_DT
reconciliation_NOMZ
of_PIN
the_DT
provision_NN
for_PIN
income_NN
taxes_NN
with_PIN
the_DT
amount_NN
computed_VBN [WZPAST]
by_PIN
applying_VBG
the_DT
statutory_JJ
income_NN
tax_NN
rate_NN
30_CD
%_NN
for_PIN
2002_CD
and_CC
2001_CD
and_CC
30.2_CD
%_NN
for_PIN
2000_CD
to_PIN
loss_NN
before_IN
taxation_NOMZ
,_,
using_VBG
UK_NN
GAAP_NN
measurement_NOMZ
principles_NN
,_,
is_VPRT
as_IN
follows_VPRT
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Income_NN
tax_NN
expense_NN
computed_VBD
at_PIN
statutory_JJ
income_NN
tax_NN
rate_NN
9,529_CD
3,531_CD
2,503_CD
Permanent_JJ
differences_NN
1,041_CD
1,205_CD
549_CD
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
in_PIN
respect_NN
of_PIN
research_NN
and_PHC
development_NOMZ
tax_NN
credit_NN
claimed_VBD [PUBV]
3,557_CD
Other_JJ
164_CD
Change_NN
in_PIN
valuation_NOMZ
allowance_NN
10,570_CD
4,736_CD
3,216_CD
Credit_NN
for_PIN
income_NN
taxes_NN
3,557_CD
Net_JJ
deferred_JJ
taxes_NN
are_VPRT [PASS]
analyzed_VBN
as_IN
follows_VPRT
:_:
2002 2001 2000 000_CD
000_CD
000_CD
Deferred_JJ
tax_NN
assets_NN
:_:
Losses_NN
carried_VBD
forward_RB
23,658_CD
18,126_CD
13,108_CD
Excess_NN
of_PIN
tax_NN
value_NN
over_IN
book_NN
value_NN
of_PIN
fixed_JJ
assets_NN
335_CD
599_CD
Other_JJ
short_JJ
term_NN
timing_NN
differences_NN
58_CD
23_CD
23,716_CD
18,461_CD
13,730_CD
Valuation_NOMZ
allowance_NN
22,444_CD
18,461_CD
13,725_CD
Net_JJ
deferred_JJ
tax_NN
asset_NN
1,272_CD
5_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
:_:
Other_JJ
short_JJ
term_NN
timing_NN
differences_NN
5_CD
Excess_NN
of_PIN
book_NN
value_NN
over_IN
tax_NN
value_NN
of_PIN
fixed_JJ
assets_NN
1,272_CD
Net_JJ
deferred_JJ
taxes_NN
As_IN
discussed_VBN
in_PIN
Note_NN
7_CD
,_,
the_DT
Group_NN
recorded_VBD
a_DT
research_NN
and_PHC
development_NOMZ
tax_NN
credit_NN
in_PIN
the_DT
current_JJ
year_NN
._.
This_DEMO
credit_NN
results_NN
in_PIN
a_DT
surrender_NN
of_PIN
certain_JJ
lossses_NN
for_PIN
which_WDT [PIRE]
a_DT
valuation_NOMZ
allowance_NN
was_VBD [PASS]
recorded_VBN
in_PIN
the_DT
prior_JJ
year_NN
._.
The_DT
change_NN
in_PIN
valuation_NOMZ
allowance_NN
above_PLACE
includes_VPRT
the_DT
establishment_NOMZ
of_PIN
the_DT
valuation_NOMZ
allowance_NN
for_PIN
the_DT
current_JJ
year_NN
and_CC
the_DT
decrease_NN
in_PIN
the_DT
valuation_NOMZ
allowance_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
surrender_NN
of_PIN
prior_JJ
year_NN
losses_NN
._.
The_DT
Group_NN
,_,
to_PIN
the_DT
extent_NN
it_PIT
is_VPRT [BEMA]
eligible_PRED
,_,
will_PRMD
continue_VB
to_TO
record_VB
research_NN
and_PHC
development_NOMZ
tax_NN
credits_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
become_VPRT
estimable_JJ
._.
As_IN
at_PIN
30_CD
September_NN
2002_CD
the_DT
Group_NN
had_VBD
approximately_RB
79_CD
million_CD
of_PIN
tax_NN
losses_NN
available_JJ
to_TO
carry_VB
forward_RB
indefinitely_RB
against_PIN
future_JJ
trading_GER
profits_NN
._.
68_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
27_CD
Reconciliation_NOMZ
to_PIN
US_FPP1
GAAP_NN
continued_VBD
Recently_TIME
issued_VBN
accounting_GER
pronouncements_NOMZ
In_PIN
August_NN
2001_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
issued_VBD
SFAS_NN
144_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
,_,
which_WDT [SERE]
addresses_VPRT
financial_JJ
accounting_GER
and_CC
reporting_VBG [PUBV]
for_PIN
the_DT
impairment_NOMZ
or_CC
disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
and_PHC
supersedes_NN
SFAS_NN
121_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
and_CC
for_PIN
Long-Lived_NN
Assets_NN
to_TO
be_VB [PASS]
Disposed_VBN
Of_PIN [STPR]
,_,
and_ANDC
the_DT
accounting_GER
and_PHC
reporting_GER
provisions_NN
of_PIN
APB_NN
Opinion_NN
No._NN
._.
30_CD
,_,
Reporting_GER
the_DT
Results_NN
of_PIN
Operations_NOMZ
,_,
for_PIN
a_DT
disposal_NN
of_PIN
a_DT
segment_NOMZ
of_PIN
a_DT
business_NOMZ
._.
SFAS_NN
144_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
December_NN
2001_CD
,_,
with_PIN
earlier_TIME
application_NOMZ
encouraged_VBD
._.
We_FPP1
expect_VPRT [PRIV]
to_TO
adopt_VB
SFAS_NN
144_CD
as_IN
of_PIN
1_CD
October_NN
2002_CD
and_CC
we_FPP1
do_VPRT
not_XX0
expect_VB [PRIV]
that_THVC
the_DT
adoption_NOMZ
of_PIN
the_DT
Statement_NOMZ
will_PRMD
have_VB
a_DT
significant_JJ
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
In_PIN
April_NN
2002_CD
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
issued_VBD
SFAS_NN
145_CD
,_,
Rescission_NN
of_PIN
FASB_NN
Statements_NOMZ
No._NN
._.
64_CD
,_,
Amendment_NOMZ
to_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
SFAS_NN
145_CD
streamlines_NN
the_DT
reporting_GER
of_PIN
debt_NN
extinguishments_NOMZ
and_CC
requires_VPRT [SUAV]
that_THVC
only_DWNT
gains_NN
and_CC
loses_VPRT
from_PIN
extinguishments_NOMZ
meeting_VBG [WZPRES]
the_DT
criteria_NN
in_PIN
Accounting_GER
Policies_NN
Board_NN
Opinion_NN
30_CD
would_PRMD
be_VB [PASS]
classified_VBN
as_IN
extraordinary_JJ
._.
Thus_CONJ
,_,
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
extinguishments_NOMZ
that_TSUB
are_VPRT
part_NN
of_PIN
a_DT
companys_NN
recurring_VBG [WZPRES]
operations_NOMZ
would_PRMD
not_XX0
be_VB [PASS]
reported_VBN [PUBV]
as_IN
an_DT
extraordinary_JJ
item_NN
._.
SFAS_NN
145_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
May_POMD
2002_CD
with_PIN
earlier_TIME
adoption_NOMZ
encouraged_VBD
._.
We_FPP1
do_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
145_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
SFAS_NN
146_CD
,_,
Accounting_GER
for_PIN
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
was_VBD [PASS]
issued_VBN
in_PIN
June_NN
2002_CD
and_CC
addresses_NN
accounting_GER
and_PHC
processing_GER
for_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
and_PHC
nullifies_NN
Emerging_VBG [WZPRES]
Issues_NN
Task_NN
Force_NN
EITF_NN
Issue_NN
94-3_CD
,_,
Liability_NOMZ
Recognition_NOMZ
for_PIN
Certain_NN
Employee_NN
Termination_NOMZ
Benefits_NN
and_CC
Other_JJ
Costs_NN
to_PIN
Exit_NN
and_PHC
Activity_NOMZ
including_VBG [WZPRES]
Certain_NN
Costs_NN
Incurred_VBN [WZPAST]
in_PIN
a_DT
Restructuring_GER
._.
SFAS_NN
146_CD
requires_VPRT [SUAV]
that_THVC
a_DT
liability_NOMZ
for_PIN
a_DT
cost_NN
associated_VBN [WZPAST]
with_PIN
an_DT
exit_NN
or_CC
disposal_NN
liability_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
liability_NOMZ
is_VPRT [PASS]
incurred_VBN
._.
Under_IN
Issue_NN
94-3_CD
,_,
a_DT
liability_NOMZ
for_PIN
an_DT
exit_NN
cost_NN
was_VBD [PASS]
recognized_VBN [PRIV]
at_PIN
the_DT
date_NN
of_PIN
an_DT
entitys_JJ
commitment_NOMZ
to_PIN
an_DT
exit_NN
plan_NN
._.
Under_IN
SFAS_NN
146_CD
,_,
fair_JJ
value_NN
is_VPRT [BEMA]
the_DT
objective_NN
for_PIN
initial_JJ
measurement_NOMZ
of_PIN
the_DT
liability_NOMZ
._.
SFAS_NN
146_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
that_TSUB
are_VPRT [PASS]
initiated_VBN
after_IN
31_CD
December_NN
2002_CD
,_,
with_PIN
early_TIME
application_NOMZ
encouraged_VBD
._.
We_FPP1
do_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
146_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
our_FPP1
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
In_PIN
2001_CD
,_,
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
issued_VBD
SFAS_NN
141_CD
,_,
Business_NOMZ
Combinations_NOMZ
and_PHC
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
SFAS_NN
141_CD
requires_VPRT [SUAV]
the_DT
use_NN
of_PIN
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
for_PIN
all_QUAN
business_NOMZ
combinations_NOMZ
initiated_VBN
after_IN
30_CD
June_NN
2001_CD
._.
SFAS_NN
141_CD
requires_VPRT [SUAV]
intangible_JJ
assets_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
if_COND
they_TPP3
arise_VPRT
from_PIN
contractual_JJ
or_CC
legal_JJ
rights_NN
or_CC
are_VPRT [BEMA]
separable_PRED
,_,
ie_NN
,_,
it_PIT
is_VPRT [BEMA]
feasible_PRED
that_THAC
they_TPP3
may_POMD
be_VB [PASS]
sold_VBN
,_,
transferred_VBN
,_,
licensed_VBN
,_,
rented_VBN
,_,
exchanged_VBD
or_CC
pledged_VBD [SUAV]
._.
As_CONJ
a_NULL
result_NULL
,_,
it_PIT
is_VPRT [BEMA]
likely_PRED
that_THAC
more_EMPH
intangible_JJ
assets_NN
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
under_IN
SFAS_NN
141_CD
than_PIN
its_PIT
predecessor_NN
,_,
APB_NN
Opinion_NN
16_CD
,_,
although_CONC
in_PIN
some_QUAN
instances_NN
previously_TIME
recognized_VBN [PRIV] [THATD]
intangibles_NN
will_PRMD
be_VB [PASS]
subsumed_VBN
into_PIN
goodwill_NN
._.
Under_IN
SFAS_NN
142_CD
,_,
goodwill_NN
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
amortised_VBN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
,_,
but_CC
will_PRMD
be_VB [PASS]
tested_VBN
for_PIN
impairment_NOMZ
on_PIN
an_DT
annual_JJ
basis_NN
and_ANDC
whenever_RB
indicators_NN
of_PIN
impairment_NOMZ
arise_VB
._.
The_DT
goodwill_NN
impairment_NOMZ
test_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
on_PIN
fair_JJ
value_NN
,_,
is_VPRT
to_TO
be_VB [PASS]
performed_VBN
on_PIN
a_DT
reporting_VBG [PUBV]
unit_NN
level_NN
._.
A_DT
reporting_VBG [PUBV] [THATD]
unit_NN
is_VPRT [PASS]
defined_VBN
as_IN
a_DT
SFAS_NN
131_CD
operating_VBG
segment_NOMZ
or_CC
one_CD
level_NN
lower_JJ
._.
Goodwill_NN
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
allocated_VBN
to_PIN
other_JJ
long-lived_JJ
assets_NN
for_PIN
impairment_NOMZ
testing_GER
under_IN
SFAS_NN
121_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
and_CC
for_PIN
Long-Lived_NN
Assets_NN
to_TO
be_VB [PASS]
Disposed_VBN
Of_PIN [STPR]
._.
Additionally_RB
,_,
goodwill_NN
on_PIN
equity_NOMZ
method_NN
investments_NOMZ
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
amortised_VBN
:_:
however_CONJ
,_,
it_PIT
will_PRMD
continue_VB
to_TO
be_VB [PASS]
tested_VBN
for_PIN
impairment_NOMZ
in_PIN
accordance_NN
with_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
18_CD
,_,
The_DT
Equity_NOMZ
Method_NN
of_PIN
Accounting_GER
for_PIN
Investments_NOMZ
in_PIN
Common_NN
Stock_NN
._.
Under_IN
SFAS_NN
142_CD
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
lives_NN
will_PRMD
not_XX0
be_VB [PASS]
amortised_VBN
._.
Instead_CONJ
they_TPP3
will_PRMD
be_VB [PASS]
carried_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
market_NN
value_NN
and_CC
tested_VBN
for_PIN
impairment_NOMZ
at_PIN
least_JJ
annually_RB
._.
All_QUAN
other_JJ
recognized_VBN [PRIV] [THATD]
intangible_JJ
assets_NN
will_PRMD
continue_VB
to_TO
be_VB [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
._.
SFAS_NN
142_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
December_NN
2001_CD
although_CONC
goodwill_NN
on_PIN
business_NOMZ
combinations_NOMZ
consummated_VBN
after_IN
1_CD
July_NN
2001_CD
will_PRMD
not_XX0
be_VB [PASS]
amortised_VBN
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
141_CD
and_CC
142_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
any_QUAN
material_NN
impact_NN
upon_PIN
the_DT
Groups_NN
results_NN
._.
